2024-07-31T15:17:24+00:00 2023-09-30 346565596 ERNST & YOUNG US LLP 200 CLARENDON STREET BOSTON MA 021165072 990 2022-10-01 042263040 Dana-Farber Cancer Institute Inc DANA 6176323000 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 MICHAEL L RENEY CFO & ASSISTANT TREASURER 6176323000 2024-07-31 true George Pagano P01978122 6172662000 2024-07-25 2022 2024-08-08 14:25:15Z LAURIE H GLIMCHER MD 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 3391207978 false X WWW.DANA-FARBER.ORG X 1951 MA SEE SCHEDULE O 71 70 8690 500 0 0 702430542 761032475 1911183785 2278805851 928841 4887533 54541425 342861910 2669084593 3387587769 6990590 8080255 0 0 807894359 948622406 3929270 5540361 48307713 1739890313 2040560837 2558704532 3002803859 110380061 384783910 4291020227 4735245065 1487687279 1374670226 2803332948 3360574839 SEE SCHEDULE O false false 1917922944 0 2278805851 CLINICAL CARE - SEE SCHEDULE O 764096554 0 0 RESEARCH - SEE SCHEDULE O 40394564 8080255 0 COMMUNITY BENEFITS - SEE SCHEDULE O 2722414062 true true false true false false false false true true false false true true false false true false false true false false true true false true true true true true true false false false false false true false false false false true false false false true true true true true false true X 686 0 true 8690 true true true true CJ false false false true true false false false false true false X 71 70 true false false false false false false true true false false true true true true true true true true false CA FL GA AL IL KS KY LA MD MA MI MN MS NH NJ NM NC ND OR SC TN UT WI X MELISSA CHAMMAS 6176323000 450 BROOKLINE AVE BP418 BOSTON MA 02115 JOHN J O'CONNOR Trustee & Treasurer 2.0 4.0 X X 0 0 0 JOSHUA BEKENSTEIN Trustee & Chairman 2.0 4.0 X X 0 0 0 Laurie H Glimcher MD Trustee, President & CEO 44.0 6.0 X X 2000525 0 338932 Monica Chandra Trustee & Secretary (AS OF 7/31/23) 1.0 2.0 X X 0 0 0 Richard Lubin Trustee & Vice-Chairman 2.0 0.0 X X 0 0 0 Afsaneh Beschloss Trustee 1.0 0 X 0 0 0 Alison Jaffe Trustee 1.0 0 X 0 0 0 Amy Berylson Trustee 1.0 0 X 0 0 0 Amy Kyle ESQ Trustee 1.0 0 X 0 0 0 Andrew Janower Trustee 1.0 0 X 0 0 0 Andrew Kaplan Trustee 1.0 0 X 0 0 0 Beth Terrana Trustee 1.0 0 X 0 0 0 Betty Ann Blum Trustee 1.0 0 X 0 0 0 Bradley Lucas Trustee 1.0 0 X 0 0 0 Brian Knez Trustee 1.0 0 X 0 0 0 Christopher Hadley Trustee 1.0 0 X 0 0 0 Demond Martin Trustee 1.0 0 X 0 0 0 Doug Grip Trustee 1.0 0 X 0 0 0 Elizabeth Clymer Trustee (as of 1/30/23) 1.0 0 X 0 0 0 Eric Miller Trustee 1.0 0 X 0 0 0 Eric Schlager Trustee 1.0 0 X 0 0 0 Esta Stecher Trustee 1.0 0 X 0 0 0 Fatima Penrose Trustee 1.0 0 X 0 0 0 Frank Laukien Trustee (as of 7/31/23) 49.0 0.0 X 0 0 0 Frederica Williams Trustee 1.0 0 X 0 0 0 Gary Prado Trustee (as of 1/30/23) 1.0 0 X 0 0 0 Harvey Berger MD Trustee 1.0 0 X 0 0 0 Hise Gibson Trustee 1.0 0 X 0 0 0 James McCann Trustee 1.0 0 X 0 0 0 Jane Brock-Wilson Trustee 1.0 0 X 0 0 0 Jane Jamieson Trustee 1.0 0 X 0 0 0 Jennifer Perini Trustee 1.0 0 X 0 0 0 Jessica Knez Trustee 1.0 0 X 0 0 0 Jill Greenthal Trustee 1.0 0 X 0 0 0 Jodi Walker Trustee 1.0 0 X 0 0 0 Jose Aguerrevere Trustee 1.0 0 X 0 0 0 Karen Daley PHD MPH RN FANN Trustee 1.0 0 X 0 0 0 Karen Hale Trustee (as of 1/30/23) 1.0 0 X 0 0 0 Karen Linde Packman Trustee 1.0 0 X 0 0 0 Kate Gulliver Trustee 1.0 0 X 0 0 0 Kevin DaSilva Trustee 1.0 0 X 0 0 0 Kimberly Sherman Stamler Trustee 1.0 0 X 0 0 0 Laura Sen Trustee 1.0 0 X 0 0 0 Levi Garraway Trustee (as of 7/31/23) 1.0 0 X 0 0 0 Lisa Ferraro Trustee 1.0 0 X 0 0 0 Lori Whelan Trustee, Vice Chairman (AS OF 12/29/23) 1.0 0 X 0 0 0 Louise Svanberg Trustee 1.0 0 X 0 0 0 Mary Ann Tocio Trustee 1.0 0 X 0 0 0 Meg Reynolds Trustee 1.0 0 X 0 0 0 Michael Eisenson Trustee 1.0 0 X 0 0 0 Michael Trotsky Trustee 1.0 0 X 0 0 0 Moria Forbes Trustee 1.0 0 X 0 0 0 Nancy Gibson Trustee 1.0 0 X 0 0 0 Nancy Lotane Trustee 1.0 0 X 0 0 0 Paul Marcus Trustee 1.0 0 X 0 0 0 Peter Palandjian Trustee 1.0 0 X 0 0 0 Phillip Gross Trustee 1.0 0 X 0 0 0 Robert Reynolds Trustee 1.0 0 X 0 0 0 Robert Sachs Trustee 1.0 0 X 0 0 0 Robert Stansky Trustee 1.0 0 X 0 0 0 Roger Berkowitz Trustee (END 1/30/23) 1.0 0 X 0 0 0 Ronald Sullivan Trustee 1.0 0 X 0 0 0 Sandra Stratford MD Trustee 1.0 0 X 0 0 0 Stephen Fine Trustee 1.0 0 X 0 0 0 Stephen Koster ESQ Trustee 1.0 0 X 0 0 0 Steven Koppel Trustee 1.0 0 X 0 0 0 Susan Alexander ESQ Trustee 1.0 0 X 0 0 0 Susan Poduska Trustee 1.0 0 X 0 0 0 Sushil Tuli Trustee 1.0 0 X 0 0 0 Theodore Pasquarello Trustee 1.0 0 X 0 0 0 Timothy Cohen Trustee 1.0 0 X 0 0 0 Tracey McCain ESQ Trustee 1.0 0 X 0 0 0 Jennifer Willcox ESQ Asst Secretary & General Counsel 50.0 0.0 X 498130 0 20595 Michael L Reney CFO and Assistant Treasurer 44.0 6.0 X 1020648 0 46591 William Hahn MD PHD COO & EVP 48.0 2.0 X 1111718 0 46513 Barrett J Rollins MD PHD Sr. Advisor President & CEO 50.0 0.0 X 529359 0 63728 Benjamin Ebert MD PhD CHAIR OF MEDICAL ONCOLOGY 50.0 0.0 X 200039 0 13049 Craig A Bunnell MD Chief Medical Officer 50.0 0.0 X 877070 0 49910 Jeffrey Meyerhardt MD MPH Chief Clinical Research Officer 50.0 0.0 X 586399 0 81024 Kevin Haigis Chief Scientific Officer 50.0 0.0 X 643658 0 47289 Maria Megdal SVP Chief Administrative Officer 50.0 0.0 X 619519 0 62384 Melany Duval SVP & Chief Philanthropy Officer 50.0 0.0 X 934299 0 62381 Sylvia A Bartel RPh MHP VP of Pharmacy Services 50.0 0.0 X 358221 0 73821 Wendy Gettleman VP of Facilities Management & Real Estate 50.0 0.0 X 374794 0 80755 Bruce Johnson MD Sr. Advisor To President & CEO 49.0 1.0 X 744812 0 66936 Mary-Ellen Taplin MD Chair Executive Committee for Clinical Research 50.0 0.0 X 714051 0 57839 Michael Constantine MD Milford Med Dir-Hematology/Oncology 50.0 0.0 X 773509 0 65744 Robert Soiffer MD Chair Executive Committee for Clinical Programs 50.0 0.0 X 803536 0 63739 Scott Armstrong MD Chair of Pediatric Oncology 50.0 0.0 X 801450 0 73627 Elizabeth Liebow Former Key Employee 0.0 0.0 X 508850 0 68051 John O Chesley ESQ Counsel 50.0 0.0 X 242667 0 35 John Ryan ESQ Former Officer 0.0 0.0 X 164347 0 9829 Richard S Boskey ESQ Former Officer 0.0 0.0 X 108175 0 0 14615776 0 1392772 2105 true true false BRIGHAM AND WOMEN'S HOSPITAL 399 Revolution Drive Ste 645 SOMERVILLE MA 02145 MEDICAL SERVICES 219939406 MCKESSON SPECIALITY CARE DISTRIBUTION 15212 Collections Center Dr CHICAGO IL 60693 SPECIALITY DRUG DISTR. SER. 29533396 SOUTH SHORE HOSPITAL 55 Fogg Road South Weymouth MA 02190 MEDICAL SERVICES 27594757 CARDINAL HEALTH 7611 Brandon Woods Blvd Baltimore MD 21226 MEDICAL SERVICES 26368160 CARDINAL HEALTH 110 INC 11 Centennial Drive Peabody MA 019616041 MEDICAL SERVICES 19257129 626 141096 25976340 816813 195987199 538111027 20040844 761032475 NET PATIENT SERVICE REVENUE 621110 2268005791 2268005791 NETWORK COLLABORATION 900099 7225923 7225923 LINAC 621500 3574137 3574137 0 0 0 0 2278805851 4887533 4887533 328166726 328166726 1446928 1446928 0 1446928 1446928 0 0 499572 25976340 3620209 -3120637 -3120637 PARKING LOT REVENUE 812930 4855402 4855402 FOOD SERVICE REVENUE 722514 4388191 4388191 DISTRIBUTION FROM DFMGBCC 900099 4000000 4000000 3125300 0 0 3125300 16368893 3387587769 2278805851 0 347749443 4067247 4067247 4013008 4013008 0 0 9754379 3194746 5625334 934299 1768851 1253662 515189 753068322 636406197 86835239 29826886 45986419 35339598 8834144 1812677 85085411 65386352 16345191 3353868 52959024 40697898 10173605 2087521 4983036 4529234 453802 15244591 11499703 3694028 50860 930956 930956 0 718727 718727 5540361 5540361 113431213 83752065 29597550 81598 12056100 8946348 1477375 1632377 32219350 25950818 5110373 1158159 87745193 83882119 3829290 33784 151911052 126834124 25074068 2860 10922587 10102316 721834 98437 6214224 2891998 2348835 973391 27649883 27237880 412003 94439039 84856058 9581744 1237 7807080 313400 7493680 PHARMACEUTICALS 1090875504 1090875504 MEDICAL SUPPLIES 158388679 157997201 391478 OTHER PATIENT CARE EXPENSE 40628791 40628791 BAD DEBT EXPENSE 9677396 9677396 174717436 161361672 12636366 719398 3002803859 2722414062 232082084 48307713 65115214 89329951 62120796 86742438 260144499 302351892 682778 479137 0 0 75159880 82174522 84658692 106554859 2228765539 1295484736 956608769 933280803 0 0 7894580 7894580 2778635019 3126436883 4291020227 4735245065 234183543 212881914 494845000 487342000 0 0 71236000 69357000 687422736 605089312 1487687279 1374670226 X 1364120082 1735209356 1439212866 1625365483 2803332948 3360574839 4291020227 4735245065 X 384783910 172457981 X false true X true true true X 604363420 629412126 726297460 702430542 761032475 3423536023 0 0 604363420 629412126 726297460 702430542 761032475 3423536023 0 3423536023 101304972 52614894 113415703 44851524 334501187 646688280 88157 126581 93395 65661 0 373794 14052058 14915439 7706225 13596972 16868465 67139159 4137737256 8387236943 0.8274 0.8906 X Schedule A, Part II, Line 10 Other Income DESCRIPTION - PARKING LOT REVENUE, COLUMN A - 6073362.0, COLUMN B - 3877282.0, COLUMN C - 3167144.0, COLUMN D - 4721708.0, COLUMN E - 4855402.0, COLUMN F - 22694898.0; DESCRIPTION - FOOD SERVICE REVENUE, COLUMN A - 4291088.0, COLUMN B - 2743883.0, COLUMN C - 2516332.0, COLUMN D - 3633966.0, COLUMN E - 4388191.0, COLUMN F - 17573460.0; DESCRIPTION - SURPLUS CAPITAL DISTRIBUTION, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 0.0, COLUMN D - 1820768.0, COLUMN E - 0.0, COLUMN F - 1820768.0; DESCRIPTION - MISCELLANOUS REVENUE, COLUMN A - 1661376.0, COLUMN B - 7376177.0, COLUMN C - 1067783.0, COLUMN D - 2815275.0, COLUMN E - 3125300.0, COLUMN F - 16045911.0; DESCRIPTION - FUNDRAISING EVENTS, COLUMN A - 913163.0, COLUMN B - 270462.0, COLUMN C - 256368.0, COLUMN D - 605255.0, COLUMN E - 499572.0, COLUMN F - 2544820.0; DESCRIPTION - DISTRIBUTION FROM DFMGBCC, COLUMN A - 0.0, COLUMN B - 0.0, COLUMN C - 0.0, COLUMN D - 0.0, COLUMN E - 4000000.0, COLUMN F - 4000000.0; DESCRIPTION - BOUTIQUE, COLUMN A - 1113069.0, COLUMN B - 647635.0, COLUMN C - 698598.0, COLUMN D - 0.0, COLUMN E - 0.0, COLUMN F - 2459302.0; RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true true false false false true 424475 true 294252 false false 718727 false Schedule C, Part II-B VAN SCOYOC & ASSOCIATES PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DANA-FARBER CANCER INSTITUTE, INC. ("DFCI"). ALSTON & BIRD LLP PROVIDED FEDERAL LEGISLATIVE CONSULTING FOR DFCI. MCDERMOTT, QUILTY & MILLER, LLP PROVIDED STATE LEGISLATIVE AND GOVERNMENT RELATIONS CONSULTING FOR DFCI. CONFERENCE OF BOSTON TEACHING HOSPITALS PROVIDED STATE AND FEDERAL LOBBYING SUPPORT TO DFCI. ALLIANCE OF DEDICATED CANCER CENTERS REPRESENTS THE NATION'S TEN FREESTANDING CANCER CENTERS. WE WORK TOGETHER ON FEDERAL REGULATORY, LEGISLATIVE, AND REIMBURSEMENT ISSUES UNIQUE TO DEDICATED CANCER CENTERS. CQ ROLL CALL PROVIDES GRASSROOTS ADVOCACY SOFTWARE USED FOR EMAILS AND ACTION ALERTS ON ADVOCACY ISSUES WHICH ARE SENT TO MEMBERS OF DANA-FARBER'S LEGISLATIVE ACTION NETWORK (LAN). DFCI'S LAN ADVOCATES FOR LEGISLATION AND POLICIES THAT IMPROVE THE LIVES OF CANCER PATIENTS. DFCI IS A MEMBER OF THE AMERICAN HOSPITAL ASSOCIATION AND THE MASSACHUSETTS HOSPITAL ASSOCIATION, NOT-FOR-PROFIT ORGANIZATIONS THAT REPRESENT AND ADVOCATE FOR THE COLLECTIVE INTERESTS OF THEIR MEMBER HOSPITALS AND HEALTH SYSTEMS THROUGH LEADERSHIP IN PUBLIC ADVOCACY, EDUCATION, AND INFORMATION. A PORTION OF THE MEMBERSHIP DUES TO THESE ORGANIZATIONS ARE USED FOR LOBBYING ACTIVITIES. ON OCCASION, DFCI EXECUTIVE LEADERSHIP MEET WITH STATE AND FEDERAL ELECTED OFFICIALS TO ADVOCATE FOR THE PASSAGE OF LEGISLATION AND FUNDING TO ADVANCE CANCER RESEARCH AND TREATMENT, AND LEGISLATION TO SUPPORT SERVICES FOR CANCER PATIENTS AND CANCER SURVIVORS. IN ADDITION, DFCI SUBMITS LETTERS AND/OR TESTIMONY TO ELECTED OFFICIALS AND POLICY MAKERS ON THESE ISSUES. 430270000 18963000 38462000 11349881 476345119 479196000 29347000 -55371000 22902000 430270000 357421000 14528000 122237000 14990000 479196000 313020000 21879000 41043000 18521000 357421000 301578000 11140000 18454000 18152000 313020000 0.0 0.6559 0.3441 false true true 17067029 17067029 1314222095 713279539 600942556 359954195 163029067 196925128 488326811 419176130 69150681 49195409 49195409 933280803 INTEREST IN DANA-FARBER, INC. 2664187088 RIGHT OF USE - NET OPERATING LEASES 335097463 RESEARCH RECEIVABLES 80460201 MISCELLANEOUS ASSETS 46692131 INTEREST IN DFCCN 3126436883 OPERATING LEASE LIABILITIES 358964640 RESEARCH ADVANCES 148873205 AMOUNTS DUE THIRD PARTY PAYOR 57105269 MISCELLANEOUS LIABILITIES 25434198 SWAP VALUATION LIABILITY 12513000 PROVISION FOR MEDICAL MALPRACTICE CLAIMS 2199000 605089312 Schedule D, Part V, Line 4 Intended uses of endowment funds DANA-FARBER, INC. ("DFI") A RELATED ORGANIZATION OF DANA-FARBER CANCER INSTITUTE, INC. ("DFCI") HOLDS THE ENDOWMENTS FOR DFCI. AS DESCRIBED IN THE CONSOLIDATED AUDITED FINANCIAL STATEMENTS, DFCI'S ENDOWMENTS CONSIST SOLELY OF DONOR-RESTRICTED ENDOWMENT FUNDS ESTABLISHED FOR PURPOSES DIRECTLY RELATED TO DFCI'S EXEMPT MISSION AND PURPOSES. AS REQUIRED BY GENERALLY ACCEPTED ACCOUNTING PRINCIPLES, NEW ASSETS ASSOCIATED WITH ENDOWMENT FUNDS ARE CLASSIFIED AND REPORTED BASED ON THE EXISTENCE OR ABSENCE OF DONOR-IMPOSED RESTRICTIONS. ALL USES OF DFCI'S ENDOWMENT FUNDS ARE IN FURTHERANCE OF DFCI'S EXEMPT MISSION AND PURPOSES. Europe (Including Iceland and Greenland) 0 0 Program Services Subcontracted Research 4967000 East Asia and the Pacific 0 0 Program Services Subcontracted Research 1333000 North America (Canada & Mexico only) 0 0 Program Services Subcontracted Research 1047000 South Asia 0 0 Program Services Subcontracted Research 991000 South America 0 0 Program Services RESEARCH AND EDUCATION 501000 Sub-Saharan Africa 0 0 Program Services Subcontracted Research 432000 East Asia and the Pacific 0 0 Program Services RESEARCH AND EDUCATION 321000 Middle East and North Africa 0 0 Program Services Subcontracted Research 104000 Middle East and North Africa 0 0 Program Services RESEARCH AND EDUCATION 70000 Central America and the Caribbean 0 0 Program Services Subcontracted Research 25000 0 0 0 0 0 0 9791000 0 9791000 false false true false false true Schedule F, Part I, Line 3 Method used to account for expenditures on org's financial statements CENTRAL AMERICA AND THE CARIBBEAN-Accrual; EAST ASIA AND THE PACIFIC-Accrual; EUROPE (INCLUDING ICELAND AND GREENLAND)-Accrual; MIDDLE EAST AND NORTH AFRICA-Accrual; NORTH AMERICA (CANADA & MEXICO ONLY)-Accrual; SOUTH AMERICA-Accrual; SOUTH ASIA-Accrual; SUB-SAHARAN AFRICA-Accrual X X X X X X X true Creative Direct Response 4200 Parliament Place Third Floor Lanham MD 20706 Direct Mail false 7662000 3696551 3965449 Charles River Interactive 900 Chelmsford St Tower III 10th Fl Lowell MA 01851 Social Media Consulting false 1068446 -1068446 Grenzebach Glier & Assoc 200 South Michican Ave Ste 210 Chigaco IL 60604 Consulting false 372125 -372125 TrueSense Marketing 502 Keystone Sr Warrendale PA 15086 Direct Mail false 258839 -258839 In Voices LLC dba Good to Go (GTG) 314 Elliot St Milton MA 02186 New special event and online fundraising strategies false 144400 -144400 7662000 5540361 2121639 CA CO CT FL GA AL HI ID IL IA KS KY LA ME AK MD MA MI MN MS MO NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN UT VT VA AR WA WV WI BMJF Walk 9893955 9716728 177227 335905 50918 4970 1179802 DFMC 8082241 7933871 148370 175050 17249 628608 10 8358341 8184366 173975 1395 111474 45188 4150 1065500 26334537 25834965 499572 1395 622429 113355 9120 2873910 3620209 -3120637 true true X true X true X true true true false true true 23362890 18324237 5038653 0.0017 131826277 97320559 34505718 0.0115 0 0.0 0 0 155189167 115644796 39544371 0.0132 8598886 8598886 0.0029 6782964 1175118 5607846 0.0019 0 0.0 831339198 681198997 150140201 0.0502 3696623 3696623 0.0012 0 0 850417671 682374115 168043556 0.0561 0 0 1005606838 798018911 207587927 0.0694 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0 0 0 0 0.0 true 9677396 96774 502305997 560662859 -58356862 X true true 1 1 DANA-FARBER CANCER INSTITUTE INC 450 BROOKLINE AVE BOSTON MA 02215 WWW.DANA-FARBER.ORG 2335 X X X DANA-FARBER CANCER INSTITUTE INC 1 false false true X X X X X X X X X 22 true false false true X https://www.dana-farber.org/community-health X true 22 true https://www.dana-farber.org/community-health/community-health-needs-assessment false true X 150.0 300.0 X true true X X X true X dfci.widen.net/s/jswr2dzbsq/financial-assistance-full-policy.pdf X dfci.widen.net/s/frfmzt8dws/financial-assistance-application.pdf X dfci.widen.net/s/h5lsvvfbw9/financial-assistance-summary.pdf X X X X X X true X false X X X true X false false Schedule H, Part V, Section B, Line 5 Facility , 1 Facility , 1 - Dana-Farber Cancer Institute ("DFCI"). IN 2022, DFCI'S BOARD OF TRUSTEES APPROVED THE 2022-2025 CANCER-FOCUSED COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) AND IMPLEMENTATION PLAN TO ENSURE THAT OUR COLLECTIVE EFFORTS HAVE THE MAXIMUM POSSIBLE IMPACT WITHIN THE INSTITUTE'S PRIORITY NEIGHBORHOODS. DANA-FARBER'S COMMUNITY BENEFITS OFFICE RETAINED HEALTH RESOURCES IN ACTION (HRIA), A NON-PROFIT PUBLIC HEALTH CONSULTANCY ORGANIZATION IN BOSTON, TO UNDERTAKE A COMPREHENSIVE ASSESSMENT OF THE HEALTH NEEDS WITHIN OUR PRIORITY COMMUNITIES, INCLUDING HOW THOSE NEEDS ARE CURRENTLY BEING ADDRESSED AND WHERE THERE ARE OPPORTUNITIES TO ADDRESS THESE NEEDS IN THE FUTURE. DANA-FARBER'S 2022-2025 CHNA BUILDS OFF PREVIOUS EFFORTS TO GAIN A GREATER UNDERSTANDING OF THE HEALTH ISSUES FACING BOSTON RESIDENTS ACROSS THE CONTINUUM OF CANCER CARE, WITH A FOCUS ON THE CITY OF BOSTON AND DANA-FARBER'S PRIORITY NEIGHBORHOODS FOR COMMUNITY BENEFITS WORK - DORCHESTER, ROXBURY, MISSION HILL, JAMAICA PLAIN, AND MATTAPAN. THE CHNA INTEGRATES KEY FINDINGS FROM THE CITYWIDE CHNA AND DELVES MORE DEEPLY INTO THE NEEDS AND EXPERIENCES OF CANCER PATIENTS, SURVIVORS, AND CAREGIVERS THROUGHOUT THE CANCER CONTINUUM, EXPLORING BEHAVIORS AND HEALTH OUTCOMES AROUND PREVENTION, SCREENING, TREATMENT, AND SURVIVORSHIP USING SOCIAL DETERMINANTS OF HEALTH AND HEALTH EQUITY FRAMEWORKS. THE ONGOING COVID-19 PANDEMIC, WHICH HAS RESULTED IN SIGNIFICANT CHANGES AND INEQUITIES IN HEALTH, THE ECONOMY, AND THE WORKFORCE, HAS BEEN AN IMPORTANT AND EVOLVING BACKDROP TO THIS CHNA. THE PURPOSE OF THE CHNA IS TO ADVANCE COMMUNITY EFFORTS IN PRIORITY AREAS BY: ASSESSING CANCER BURDEN IN THE COMMUNITY AS WELL AS ACCESS TO AND AVAILABILITY OF CANCER-RELATED SERVICES; IDENTIFYING KEY AREAS OF SIGNIFICANT COMMUNITY NEED AND VULNERABLE POPULATIONS; EXAMINING THE IMPACT AND ROLE OF SOCIAL DETERMINANTS OF HEALTH; AND FACILITATING THE DEVELOPMENT OF MULTI-YEAR IMPLEMENTATION STRATEGIES TO GUIDE DFCI'S COMMUNITY HEALTH INITIATIVES AND COMMUNITY INVESTMENTS. IN ADDITION TO IDENTIFYING BROAD HEALTH ISSUES FACING RESIDENTS, THE 2022-2025 CHNA INVESTIGATES THE FULL CONTINUUM OF CANCER CARE; IT EXPLORES DIFFERENT ASPECTS OF CARE FROM INITIAL SCREENING TO TREATMENT AND CULMINATES WITH CONSIDERATIONS OF SURVIVORSHIP. THE BOSTON CHNA-CHIP COLLABORATIVE (THE COLLABORATIVE) WAS CREATED AND LAUNCHED BY SEVERAL STAKEHOLDERS-COMMUNITY ORGANIZATIONS, HEALTH CENTERS, COMMUNITY DEVELOPMENT CORPORATIONS, HOSPITALS, AND THE BOSTON PUBLIC HEALTH COMMISSION. IN 2019, THE COLLABORATIVE CONDUCTED THE FIRST LARGE-SCALE COLLABORATIVE CITYWIDE COMMUNITY HEALTH NEEDS ASSESSMENT (BOSTON CHNA) AND COMMUNITY HEALTH IMPROVEMENT PLANNING (BOSTON CHIP) PROCESS. THE GOALS OF THE BOSTON CHNA ARE TO SYSTEMATICALLY IDENTIFY THE HEALTH-RELATED NEEDS, STRENGTHS, AND RESOURCES OF COMMUNITIES TO INFORM FUTURE PLANNING, UNDERSTAND THE CURRENT HEALTH STATUS OF BOSTON OVERALL AND ITS SUB-POPULATIONS WITHIN THEIR SOCIAL CONTEXT, AND MEET REGULATORY REQUIREMENTS FOR SEVERAL INSTITUTIONS, ORGANIZATIONS, AND AGENCIES (E.G. IRS REQUIREMENTS FOR NON-PROFIT HOSPITALS, PUBLIC HEALTH ACCREDITATION BOARD FOR HEALTH DEPARTMENTS). DURING THE CITYWIDE CHNA: AS A MEMBER OF THE STEERING COMMITTEE, DANA-FARBER WORKED CLOSELY WITH MEMBERS OF THE COLLABORATIVE TO CONDUCT A ROBUST DATA COLLECTION AND A COMMUNITY ENGAGEMENT PROCESS. THE COVID-19 PANDEMIC PLAYED AN IMPORTANT BACKDROP DURING THE ASSESSMENTS PHASE. THE 2022 CHNA'S ALSO EXPLORED HOW THE PANDEMIC AND RACIAL INJUSTICES HAVE AFFECTED COMMUNITY HEALTH NEEDS. DANA-FARBER IS COMMITTED TO MEETING THE HEALTH NEEDS OF MEDICALLY UNDERSERVED POPULATIONS AND RECOGNIZES THAT MANY OF THE POPULATIONS THAT DANA-FARBER FOCUSED ON IN ITS 2022 CHNA HAVE BEEN DISPROPORTIONATELY IMPACTED BY THE COVID-19 PANDEMIC. GIVEN THE UNPRECEDENTED NATURE OF THE COVID-19 PANDEMIC, IT IS CRITICAL NOW, MORE THAN EVER, TO UNDERSTAND COMMUNITY NEEDS, EXPERIENCES, AND OPPORTUNITIES FOR THE FUTURE. SECONDARY DATA FOR THIS REPORT COME FROM A VARIETY OF SOURCES. DATA SOURCES INCLUDE THE BOSTON BEHAVIORAL RISK FACTOR SURVEILLANCE SURVEY (BBRFSS), THE U.S. CENSUS, THE MASSACHUSETTS CANCER REGISTRY, AND VITAL RECORDS. AS PART OF THE BBRFSS, A SEPARATE COVID-19 HEALTH EQUITY SURVEY WAS CONDUCTED IN DECEMBER 2020/JANUARY 2021 BY THE BOSTON PUBLIC HEALTH COMMISSION TO BETTER UNDERSTAND EXPERIENCES AMONG RESIDENTS WHO HAVE BEEN MOST IMPACTED BY THE PANDEMIC. DATA FROM THIS COVID-19 HEALTH EQUITY SURVEY ARE ALSO INCLUDED IN THIS REPORT. THE RESEARCH AND EVALUATION OFFICE AT THE BOSTON PUBLIC HEALTH COMMISSION CONDUCTED THE DATA ANALYSIS FOR NEARLY ALL THE SECONDARY DATA ON HEALTH INDICATORS IN THIS REPORT (E.G., LIFESTYLE BEHAVIORS, SCREENING BEHAVIORS, CANCER INCIDENCE, CANCER MORTALITY). ANALYSES ARE PRESENTED AS FREQUENCIES (PERCENTAGES) AND RATES THROUGHOUT THE REPORT. ADDITIONAL DATA SOURCES INCLUDE PRESENTATIONS AND REPORTS REGARDING THE SOCIAL DETERMINANTS OF HEALTH, HEALTH OUTCOMES, AND HEALTH CARE EXPERIENCES FOR SEVERAL COMMUNITIES OF COLOR AND SEXUAL AND GENDER MINORITY POPULATIONS. THESE SOURCES INCLUDE: A 2022 PRESENTATION BY DR. DON S. DIZON, "DON'T ASK, CAN'T COUNT. ADDRESSING THE INVISIBILITY OF THE SGM COMMUNITY ACROSS THE CANCER TRAJECTORY EXPERIENCE FENWAY HEALTH AND BLACK BOSTON COVID-19 COALITION 2022 REPORT, "LEARNING FROM BOSTON'S BLACK COMMUNITY WHAT SUPPORTS ITS HEALTH, RESILIENCE, AND WELLBEING" (REFERRED TO HEREAFTER AS THE "BLACK BOSTON 2022 REPORT"); AND THE MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH'S WOMEN'S HEALTH NETWORK 2019 REPORT, "ASSESSMENT OF COLORECTAL CANCER SCREENING ATTITUDES AND PRACTICES AMONG THE ASIAN COMMUNITY IN MASSACHUSETTS." Schedule H, Part V, Section B, Line 5 Facility , 2 Facility , 2 - Dana-Farber Cancer Institute ("DFCI"). DANA-FARBER DESIGNED A QUALITATIVE KEY INFORMANT SURVEY. THIS SURVEY WAS FIELDED WITH CANCER SURVIVORS AND REPRESENTATIVES FROM ORGANIZATIONS THAT SERVE INDIVIDUALS ACROSS THE CANCER CONTINUUM. THE SURVEY AIMED TO UNDERSTAND THEIR EXPERIENCES WITH CANCER PREVENTION, CANCER CARE, AND SURVIVORSHIP; RECOMMENDATIONS FOR CANCER AND CHRONIC DISEASE PREVENTION SERVICES AND RESOURCES; THE INFLUENCE OF THE COVID-19 PANDEMIC ON ACCESS TO CANCER SCREENING AND HEALTH CARE; POTENTIAL FACILITATORS TO INCREASE CANCER SCREENING; AND RECOMMENDATIONS FOR ADDRESSING GAPS IN SERVICES AND RESOURCES FOR CANCER SURVIVORS. OF 27 PEOPLE CONTACTED, A TOTAL OF 13 CANCER SURVIVORS AND COMMUNITY STAKEHOLDERS REPRESENTING COMMUNITY-BASED, PUBLIC HEALTH, AND HEALTH CARE ORGANIZATIONS COMPLETED THIS QUALITATIVE SURVEY. DFCI WORKED WITH A VARIETY OF PARTNERS TO GATHER PRIMARY QUALITATIVE DATA THROUGH FOCUS GROUPS AND INTERVIEW DISCUSSIONS. DFCI MADE A CONCERTED EFFORT TO ENGAGE WITH POPULATIONS AND COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. ALTOGETHER, 8 FOCUS GROUPS WITH 69 PARTICIPANTS (CAREGIVERS, PATIENTS/SURVIVORS) AND 4 INTERVIEW DISCUSSIONS WERE CONDUCTED SPECIFICALLY FOR ITS CHNA. KEY THEMES FROM TWO ADDITIONAL DATA SOURCES WERE ALSO ANALYZED AND ARE INCORPORATED INTO THIS CHNA. FIRST, THE BOSTON BREAST CANCER EQUITY COALITION (BBCEC) SHARED KEY THEMES FROM 9 INTERVIEWS CONDUCTED WITH SMALL, LOCAL NON-PROFIT ORGANIZATIONS WHO SUPPORT BIPOC COMMUNITIES. SECOND, THE BOSTON PUBLIC HEALTH COMMISSION ALSO SHARED KEY FINDINGS FROM A FOCUS GROUP CONDUCTED WITH THEIR 10-MEMBER RACIAL HEALTH EQUITY ADVISORY COMMITTEE (RHEAC) TO GARNER INPUT TO INFORM THE CREATION OF A LUNG CANCER COMMUNICATION CAMPAIGN. THIS REPORT ALSO INTEGRATES FINDINGS FROM DATA COLLECTED AS PART OF THE 2022 BOSTON CHNA-CHIP COLLABORATIVE'S PROCESS. THE COLLABORATIVE'S COMMUNITY ENGAGEMENT WORK GROUP FACILITATED 29 VIRTUAL AND IN-PERSON FOCUS GROUP DISCUSSIONS WITH A TOTAL OF 309 RESIDENTS WHO HAVE BEEN DISPROPORTIONATELY BURDENED BY SOCIAL, ECONOMIC, AND HEALTH CHALLENGES INCLUDING: YOUTH AND ADOLESCENTS, OLDER ADULTS, PERSONS WITH DISABILITIES, LOW-RESOURCED INDIVIDUALS AND FAMILIES, LGBTQIA+ POPULATIONS, RACIALLY/ETHNICALLY DIVERSE POPULATIONS (E.G., AFRICAN AMERICAN, LATINO, HAITIAN, CAPE VERDEAN, VIETNAMESE, CHINESE), LIMITED-ENGLISH SPEAKERS, IMMIGRANT AND ASYLEE COMMUNITIES, FAMILIES AFFECTED BY INCARCERATION AND/OR VIOLENCE, AND VETERANS. SOME FOCUS GROUPS WERE CONDUCTED IN LANGUAGES OTHER THAN ENGLISH, INCLUDING SPANISH, CHINESE, AND VIETNAMESE. COLLABORATIVE MEMBERS ALSO CONDUCTED KEY INFORMANT INTERVIEWS WITH 62 INDIVIDUALS. THESE INTERVIEWEES INCLUDED LEADERS AND STAFF FROM PUBLIC HEALTH, HEALTH CARE, BEHAVIORAL HEALTH, THE FAITH COMMUNITY, IMMIGRANT SERVICES, HOUSING ORGANIZATIONS, ECONOMIC DEVELOPMENT, COMMUNITY DEVELOPMENT, RACIAL JUSTICE ORGANIZATIONS, SOCIAL SERVICE ORGANIZATIONS, EDUCATION, COMMUNITY COALITIONS, THE BUSINESS COMMUNITY, CHILDCARE CENTERS, ELECTED GOVERNMENT OFFICES, AND OTHERS. THE STRATEGIES AND GOALS OUTLINED IN OUR 2022-2025 CHNA IMPLEMENTATION PLAN ARE A NATURAL CONTINUATION OF THE EFFORTS IDENTIFIED IN OUR 2020-2023 PLAN AND ARE DESIGNED TO ADVANCE AND STRENGTHEN OUR EXISTING COMMUNITY-BASED INITIATIVES WHILE ALSO SEEKING TO ADDRESS THE SOCIAL DETERMINANTS OF HEALTH THROUGH COLLABORATIVE PARTNERSHIPS. Schedule H, Part V, Section B, Line 11 Facility , 1 Facility , 1 - Dana-Farber Cancer Institute ("DFCI"). DFCI CAPTURED AND ADDRESSED ALL THE NEEDS IDENTIFIED IN THE COMMUNITY HEALTH NEEDS ASSESSMENT (CHNA) AND THE ACCOMPANYING IMPLEMENTATION PLAN. A FULL DESCRIPTION OF OUR PROGRAMS IS AVAILABLE ON OUR WEBSITE BOTH IN THE COMMUNITY HEALTH NEEDS ASSESSMENT REPORT AND IN THE COMMUNITY HEALTH IMPLEMENTATION PLAN. CANCER REMAINS A LEADING CAUSE OF DEATH IN BOSTON. WHILE THE CHNA FINDINGS INDICATE THAT COLLECTIVE EFFORTS TO ADVANCE CANCER SCREENING AND PREVENTION ARE MAKING A DIFFERENCE, THE OVERALL BURDEN OF CANCER ACROSS ALL TYPES IS SIGNIFICANT AND MORE EFFORT IS NEEDED TO REDUCE THE CANCER BURDEN AND ADDRESS DISPARITIES. DANA-FARBER RECOGNIZES THAT OUR EFFORTS MUST GO BEYOND CANCER CARE AND TREATMENT, AND AS SUCH, WE WILL CONTINUE OUR UNWAVERING COMMITMENT TO REDUCING THE CANCER BURDEN AND PROMOTING SURVIVORSHIP. WE REMAIN COMMITTED TO EDUCATING THE COMMUNITY AND RAISING AWARENESS ABOUT THE IMPORTANCE OF CANCER PREVENTION, OUTREACH, SCREENING, EARLY DETECTION, CLINICAL TRIALS AND SURVIVORSHIP. IN ADDITION, WE WILL CONTINUE TO CONDUCT A BROAD SCOPE OF COMMUNITY-BASED RESEARCH AND EVIDENCE-BASED INTERVENTIONS THROUGH COLLABORATIVE WORK IN LOCAL NEIGHBORHOODS AND THROUGHOUT THE REGION. OUR EXPERTISE AS A COMPREHENSIVE CANCER CENTER LEADS US TO FOCUS LARGELY ON REDUCING CANCER INCIDENCE AND MORTALITY AMONG MEDICALLY UNDERSERVED POPULATIONS THROUGH OUR CLINICAL COMMUNITY SCREENING AND OUTREACH PROGRAMS, WHICH INCLUDE MOBILE MAMMOGRAPHY AND BREAST HEALTH EDUCATION, SKIN CANCER EDUCATION AND SCREENING, HPV EDUCATION AND VACCINATION, TOBACCO CESSATION AND INCREASING AWARENESS ABOUT SURVIVORSHIP IN COMMUNITIES OF COLOR. WE RECOGNIZE THAT OUR PRIORITY NEIGHBORHOODS ARE ALSO DEALING DISPROPORTIONATELY WITH CHALLENGING SITUATIONS RELATED TO SOCIAL AND ECONOMIC FACTORS, SUCH AS LIMITED EMPLOYMENT OPPORTUNITIES, SUBSTANCE ABUSE AND OPIOID ADDICTION, LOW EDUCATION LEVELS, LACK OF AFFORDABLE HOUSING, AND COMMUNITY VIOLENCE. WE WORK ON THESE BROADER ISSUES BY ADVOCATING AND BY PARTNERING WITH LOCAL COALITIONS AND COMMUNITY-BASED ORGANIZATIONS SUCH AS THE MASS HEALTH EQUITY COMPACT LED BY THE MASSACHUSETTS LEAGUE OF COMMUNITY HEALTH CENTERS. SIGNIFICANT PROGRESS HAS BEEN MADE IN ADVANCING THE GOALS SET IN OUR 2020-2023 CHNA IMPLEMENTATION PLAN. SUMMARIZED BELOW ARE EXAMPLES OF KEY ACCOMPLISHMENTS FROM THE PAST THREE YEARS, WHICH DEMONSTRATE THE COLLECTIVE IMPACT OF OUR WORK. OUR IMPACT IS GREATLY STRENGTHENED BY EMBEDDING PROGRAMMING AND SERVICES INTO THE FABRIC OF THE COMMUNITIES WE SERVE. * LAUNCHED NEW STATE OF THE ART MOBILE MAMMOGRAPHY VAN EQUIPPED WITH NEW TOMOSYNTHESIS IMAGING TECHNOLOGY. * PROVIDED 4,029 MAMMOGRAMS ON DANA-FARBER'S MAMMOGRAPHY VAN AND 1,735 MAMMOGRAMS AT DANA-FARBER'S MAMMOGRAPHY SUITE AT WHITTIER STREET HEALTH CENTER IN ROXBURY. * SUCCESSFULLY LAUNCHED NEW COMMUNITY-FACING PATIENT NAVIGATION PROGRAM, WHICH WAS PILOTED IN THE BREAST, THORACIC, AND GASTROINTESTINAL DISEASE CENTERS AND WILL BE EMBEDDED INTO ALL MAJOR CLINICAL AREAS AT DANA-FARBER. * AWARDED THE FIRST ROUND OF FUNDING FOR DANA-FARBER'S ACCESS TO SERVICES GRANTS TO 12 NONPROFIT ORGANIZATIONS IN GREATER BOSTON AND COMMITTED $1 MILLION DOLLARS TO THE HEALTHY NEIGHBORHOODS EQUITY FUND TO ADDRESS HOUSING NEEDS IN GREATER BOSTON. * COMMITTED $500K TO HEALTHY RETAIL & COMMERCE FUND TO SUPPORT HEALTHY FOOD ACCESS AND $250K TO THE BOSTON LOCAL INITIATIVES SUPPORT CORPORATION (LISC BOSTON) SMALL BUSINESS GROWTH FUND TO SUPPORT ECONOMIC EMPOWERMENT AND GROW BUSINESSES OWNED BY BLACK, LATINO, AND INDIGENOUS ENTREPRENEURS AND OTHER PEOPLE OF COLOR. * CONTINUED TO PROVIDE STREAMLINED DIAGNOSIS, TREATMENT, AND EDUCATION FOR MEDICALLY UNDERSERVED PATIENTS WITH SUSPECTED MALIGNANCIES THROUGHOUT THE CONTINUUM OF CARE THROUGH DANA-FARBER'S CANCER CARE EQUITY PROGRAM (CCEP) AT FEDERALLY QUALIFIED COMMUNITY HEALTH CENTERS. SINCE PROGRAM INCEPTION IN 2012, THE PROGRAM HAS SEEN OVER 692 PATIENTS AS NEW CONSULTS AND 507 PATIENTS IN FOLLOW-UP VISITS. * PROVIDED 348 INDIVIDUAL TOBACCO CESSATION COUNSELING SESSIONS TO 126 PATIENTS. * 104 PARTICIPANTS (84%) REPORTED THAT THEY WERE ABLE TO REDUCE THEIR TOTAL NUMBER OF CIGARETTES SMOKED PER DAY, AND 37 (28%) REPORTED BEING ABLE TO QUIT COMPLETELY. PROVIDED NICOTINE REPLACEMENT THERAPY (NICOTINE PATCHES AND LOZENGES) AND GIFT CARDS TO 49 GIFT PATIENTS ENROLLED IN THE SMOKING CESSATION PROGRAM TO ENCOURAGE INDIVIDUALS TO REDUCE THEIR TOBACCO USAGE AND QUIT SMOKING. * ENGAGED 2,233 RESIDENTS IN SUN SAFETY EDUCATION AND SKIN CANCER SCREENING. MADE CALLS TO 264 PARTICIPANTS FOR FOLLOW-UP, WITH 128 REFERRED FOR BIOPSY. * CONTINUED TO LEAD STATEWIDE MASSACHUSETTS HPV COALITION IN PARTNERSHIP WITH TEAM MAUREEN. LAUNCHED UPDATED DENTAL TOOLKIT, AVAILABLE IN 7 LANGUAGES. CONVENED APPROXIMATELY 250 MEDICAL AND DENTAL PROVIDERS, PUBLIC HEALTH PROFESSIONALS, AND COMMUNITY ADVOCATES THROUGH ANNUAL HPV-RELATED CANCER SUMMIT TO DISSEMINATE LATEST RESEARCH AND BEST PRACTICES. * PARTNERED WITH UNION CAPITAL BOSTON AND THE DANA-FARBER/HARVARD CANCER CENTER TO ENGAGE OVER 800 COMMUNITY RESIDENTS THROUGH VIRTUAL EDUCATION NIGHTS FOCUSED ON CANCER PREVENTION TOPICS. DANA-FARBER CANCER INSTITUTE |COMMUNITY HEALTH IMPLEMENTATION PLAN 9. * LAUNCHED A NEW PARTNERSHIP WITH MYHEALTHFAIR.ORG TO INCREASE VIRTUAL EDUCATION AND OUTREACH WITH THE LOCAL SPANISH-SPEAKING COMMUNITY. 9 DFBWCC AT SOUTH SHORE HOSPITAL 101 COLUMBIAN STREET SOUTH WEYMOUTH MA 02190 SATELLITE DFBWCC AT MILFORD REGIONAL MEDICAL CENTER 20 PROSPECT STREET MILFORD MA 01757 SATELLITE DFCI - CHESTNUT HILL 300 BOYLSTON STREET NEWTON MA 02459 SATELLITE DFCI - MERRIMACK VALLEY 5 BRANCH STREET METHUEN MA 01844 SATELLITE DFNH ONCOLOGY-HEMATOLOGY ELLIOTT MED CENTER 40 BUTTRICK RD S TE B LONDONDERRY NH 03053 SATELLITE DFCI AT ST ELIZABETH'S MEDICAL CNTR CUSHING PAVILION 736 CAMBRIDGE STRE ET BRIGHTON MA 02135 SATELLITE DFCI - LIBBEY PARK 51 PERFORMANCE DRIVE WEYMOUTH MA 02189 SATELLITE DFCI - MOBILE MAMMOGRAPHY SERVICE 450 BROOKLINE AVENUE BOSTON MA 02215 SATELLITE DFCI - WHITTIER STREET HEALTH CENTER 1290 TREMONT STREET ROXBURY MA 02120 SATELLITE Schedule H, Part I, Line 3c Patient education of eligibility for assistance IN ADDITION TO DETERMINING ELIGIBILITY FOR DISCOUNTED CARE BASED ON FAMILY INCOME, DFCI OFFERS ASSISTANCE TO PATIENTS WHO HAVE EXCESSIVE MEDICAL BILLS (EXCEEDING 30-40% OF FAMILY INCOME). Schedule H, Part I, Line 6a Community information THE COMMUNITY BENEFIT REPORT WAS COMPLETED BY DFCI AND IS ANNUALLY PROVIDED TO THE MASSACHUSETTS ATTORNEY GENERAL'S OFFICE, WHERE IT IS THEN MADE PUBLIC ON ITS WEBSITE. Schedule H, Part I, Line 7 State filing of community benefit report DFCI'S STATE COST REPORT WAS USED TO DEVELOP THE INSTITUTE'S COST TO CHARGE RATIO THAT WAS APPLIED TO CHARITY CARE CHARGES TO DETERMINE THE COST OF FINANCIAL ASSISTANCE (LINE 7A). LINE 7B REFLECTS THE SPECIFIC LOSS INCURRED FOR THE INSTITUTE'S MEDICAID ACTIVITY. THE INSTITUTE IS A PREEMINENT PROVIDER OF HEALTH TRAINING TO HEALTH PROFESSIONALS WHO DESIRE TRAINING IN THE SKILLS NECESSARY TO TREAT CANCER PATIENTS. THE INSTITUTE TRAINS PHYSICIANS, SCIENTISTS, MEDICAL STUDENTS AND INDIVIDUALS LOOKING TO CREATE A CAREER IN THE FIELD OF CANCER. THE AMOUNT REPORTED AS HEALTH TRAINING REPRESENT COSTS IN EXCESS OF AMOUNTS REIMBURSED BY THIRD PARTY PAYERS SUCH AS TRAINING GRANT REVENUES AND DIRECT MEDICAL EDUCATION PAYMENTS FROM THE MEDICARE PROGRAM. DEPARTMENT LEADERS SUBMIT EXPENDITURES TO COMMUNITY BENEFITS ALONG WITH A DESCRIPTION OF THE SERVICES PROVIDED TO MEDICALLY UNDERSERVED POPULATIONS. LINE 7F EXPENDITURES ARE REVIEWED BY LEADERSHIP AND IN PARTNERSHIP WITH DFCI'S OFFICE OF FINANCE, THE EXPENDITURES ARE APPROVED. THE AMOUNTS ARE CAPTURED IN THREE BUCKETS - CB EXPENDITURES (ALL PROGRAMS); LEVERAGED FUNDS (THOSE FUNDS SUPPORTED IN FULL OR PART THROUGH GRANTS/DONATIONS) AND COMMUNITY SPONSORSHIPS. Schedule H, Part V SECTION A & D DFCI'S MAIN CAMPUS IS AT 450 BROOKLINE AVE., BOSTON, MA, 02115. DFCI'S SATELLITE LOCATIONS (BELOW) EACH OPERATE UNDER THE SAME HOSPITAL LICENSE. DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT MILFORD HOSPITAL, 20 PROSPECT STREET, MILFORD, MA 01757 DANA-FARBER/BRIGHAM AND WOMEN'S CANCER CENTER AT SOUTH SHORE HOSPITAL, 101 COLUMBIAN STREET, SOUTH WEYMOUTH, MA 02190 DANA-FARBER AT ST. ELIZABETH'S MEDICAL CENTER, 736 CAMBRIDGE STREET, CUSHING PAVILION, 5TH FLOOR, BRIGHTON, MA 02135 DANA-FARBER CANCER INSTITUTE - CHESTNUT HILL, 300 BOYLSTON STREET, NEWTON, MA 02459 DANA-FARBER CANCER INSTITUTE - MERRIMACK VALLEY, 5 BRANCH STREET, METHUEN, MA 01844 DANA-FARBER CANCER INSTITUTE - FOXBOROUGH, 22 PATRIOT PLACE, FOXBOROUGH, MA, 02035 DANA-FARBER CANCER INSTITUTE - LIBBEY PARK, 51 PERFORMANCE DRIVE, WEYMOUTH, MA 02189 DANA-FARBER CANCER INSTITUTE - MOBILE MAMMOGRAPHY SERVICE, 450 BROOKLINE AVENUE, BOSTON, MA 02215 DANA-FARBER CANCER INSTITUTE - WHITTIER STREET HEALTH CENTER, 1290 TREMONT STREET, ROXBURY, MA 02120 DANA-FARBER/NEW HAMPSHIRE ONCOLOGY HEMATOLOGY ALSO OPERATES A CLINICAL LOCATION AT 40 BUTTRICK ROAD, SUITE B, LONDONDERRY, NH 03053. Schedule H, Part III Section A, Lines 2 and 3 - Bad Debt Expense IN CALCULATING BAD DEBT EXPENSE, DFCI USES A COMBINATION OF ACTUAL BAD DEBT WRITE OFFS AND HISTORICAL BAD DEBT FACTORS IN DETERMINING WHICH CURRENT ACCOUNTS RECEIVABLE ARE NOT LIKELY TO BE COLLECTED. ADDITIONALLY, DFCI DETERMINES THE AMOUNT OF BAD DEBT ATTRIBUTABLE TO INDIVIDUALS WHO ARE ELIGIBLE FOR FINANCIAL ASSISTANCE BASED ON A HISTORICAL ESTIMATE OF THE PERCENTAGE OF PATIENTS THAT HAVE QUALIFIED FOR FINANCIAL ASSISTANCE, WHICH IS APPLIED AGAINST TOTAL BAD DEBT. Schedule H, Part V, Section B, Line 20d Billing and collections DANA-FARBER DOES NOT ENGAGE IN PRESUMPTIVE ELIGIBILITY FOR ITS PATIENT FINANCIAL ASSISTANCE POLICY (FAP). THROUGH ITS PARTICIPATION IN THE MASSACHUSETTS HEALTH SAFETY NET, THE STATE SPONSORED UNCOMPENSATED PROGRAM, DANA-FARBER FIRST RELIES ON DEMONSTRATION OF INELIGIBILITY FOR MASSHEALTH PROGRAMS, SUCH AS HEALTH SAFETY NET, OR SIMILAR OUT OF STATE MEDICAID PROGRAMS, FROM PATIENTS APPLYING FOR ASSISTANCE. UPON DETERMINATION BY THE STATE AGENCY, DANA-FARBER WILL CONSIDER EACH CASE INDIVIDUALLY AND RELIES ON THE COMPLETION OF THE PATIENT FINANCIAL ASSISTANCE APPLICATION ("PFA APPLICATION") AND PROVISION OF NECESSARY SUPPORTING DOCUMENTATION. Schedule H, Part V, Section B, Line 22 Charges to FAP eligible individuals DEPENDING ON A PATIENT'S FINANCIAL SITUATION, FAP-ELIGIBLE PATIENTS WERE CHARGED BETWEEN 0% TO 30% OF BILLED CHARGES, WHICH WAS NOT MORE THAN THE AGB. IN FY23, DFCI DETERMINED AGB ON AN ANNUAL BASIS USING THE "LOOK-BACK METHOD," DESCRIBED UNDER TREASURY REGULATION SECTION 1.501(R)-5(B)(1). SPECIFICALLY, DFCI'S ANNUAL AGB PERCENTAGE WAS EQUAL TO SUM OF ALL GROSS CHARGES DURING THE PRIOR FISCAL YEAR DIVIDED BY CLAIMS PAID IN CONNECTION WITH THOSE CHARGES. FOR PURPOSES OF THE AGB CALCULATION, CLAIMS PAID INCLUDED CLAIMS FOR EMERGENCY AND MEDICALLY NECESSARY CARE PAID BY BOTH MEDICARE FEE-FOR-SERVICE AND ALL PRIVATE HEALTH INSURERS AS PRIMARY PAYERS, TOGETHER WITH ANY ASSOCIATED PORTIONS OF THESE CLAIMS PAID BY MEDICARE BENEFICIARIES OR INSURED INDIVIDUALS IN THE FORM OF CO-PAYMENTS, CO-INSURANCE OR DEDUCTIBLES. Schedule H, Part I, Line 6a Community benefit report prepared by related organization DANA-FARBER CANCER INSTITUTE ("DFCI") Schedule H, Part I, Line 7 Bad Debt Expense excluded from financial assistance calculation 9677396 Schedule H, Part III, Line 4 Bad debt expense - financial statement footnote CONSISTENT WITH THE INSTITUTE'S MISSION, CARE IS PROVIDED TO PATIENTS REGARDLESS OF THEIR ABILITY TO PAY. THE INSTITUTE HAS DETERMINED IT HAS PROVIDED IMPLICIT PRICE CONCESSIONS TO UNINSURED PATIENTS AND PATIENTS WITH OTHER UNINSURED BALANCES (E.G. COPAYS AND DEDUCTIBLES). THE IMPLICIT PRICE CONCESSIONS INCLUDED IN ESTIMATING THE TRANSACTION PRICE REPRESENT THE DIFFERENCE BETWEEN AMOUNTS BILLED TO PATIENTS AND THE AMOUNTS THE INSTITUTE EXPECTS TO COLLECT BASED ON ITS COLLECTION HISTORY WITH THOSE PATIENTS. PATIENTS WHO MEET THE INSTITUTE'S CRITERIA FOR CHARITY CARE ARE PROVIDED CARE WITHOUT CHARGE OR AT AMOUNTS LESS THAN ESTABLISHED RATES. THE INSTIUTE HAS DETERMINED THAT IT HAS PROVIDED SUFFICIENT IMPLICIT PRICE CONCESSIONS FOR THESE ACCOUNTS. PRICE CONCESSIONS, INCLUDING CHARITY CARE, ARE NOT REPORTED AS REVENUE. Schedule H, Part III, Line 8 Community benefit & methodology for determining medicare costs THE MEDICARE COST ON LINE 6 COMES FROM THE MEDICARE COST REPORT AND IS BASED ON MEDICARE'S COST FINDING PRINCIPLES AND METHODOLOGIES. WE STRONGLY BELIEVE THAT THE ENTIRE AMOUNT OF THE SHORTFALL OF $58,356,862 SHOULD BE TREATED AS A COMMUNITY BENEFIT AS THIS REPRESENTS THE INSTITUTE'S COMMITMENT TO THE ELDERLY AND DISABLED COMMUNITY BY PROVIDING SERVICES THAT ARE NOT REIMBURSED. Schedule H, Part III, Line 9b Collection practices for patients eligible for financial assistance WITHIN DFCI'S CREDIT AND COLLECTIONS POLICY THERE ARE PROVISIONS THAT DESCRIBE COLLECTION PRACTICES TO BE FOLLOWED FOR PATIENTS WHO ARE KNOWN TO QUALIFY FOR CHARITY CARE OR FINANCIAL ASSISTANCE IN ACCORDANCE WITH FEDERAL AND MASSACHUSETTS LAW. Schedule H, Part V, Section B, Line 16a FAP website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16a URL: dfci.widen.net/s/jswr2dzbsq/financial-assistance-full-policy.pdf; Schedule H, Part V, Section B, Line 16b FAP Application website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16b URL: dfci.widen.net/s/frfmzt8dws/financial-assistance-application.pdf; Schedule H, Part V, Section B, Line 16c FAP plain language summary website - DANA-FARBER CANCER INSTITUTE, INC.: Line 16c URL: dfci.widen.net/s/h5lsvvfbw9/financial-assistance-summary.pdf; Schedule H, Part VI, Line 2 Needs assessment DANA-FARBER CANCER INSTITUTE CONTINUOUSLY ASSESSES THE COMMUNITY NEEDS THROUGH OUR PARTICIPATION IN COMMUNITY COALITIONS, TASK FORCES, WORKING GROUPS AND DIRECT COMMUNICATION WITH THE COMMUNITY RESIDENTS THAT SERVE ON OUR EXTERNAL ADVISORY COMMITTEE AND ON OUR PATIENT AND FAMILY ADVISORY BOARD. A FULL DESCRIPTION OF OUR COMMUNITY ENGAGEMENT PROCESS CAN BE FOUND ON OUR WEBSITE BOTH IN THE COMMUNITY HEALTH NEEDS ASSESSMENT REPORT AND IN THE COMMUNITY HEALTH IMPLEMENTATION PLAN. Schedule H, Part VI, Line 3 Patient education of eligibility for assistance DFCI IS COMMITTED TO OFFERING FINANCIAL ASSISTANCE TO ELIGIBLE PATIENTS WHO DO NOT HAVE THE ABILITY TO PAY FOR THEIR MEDICAL SERVICES IN WHOLE OR IN PART. IN ORDER TO ACCOMPLISH THIS CHARITABLE GOAL, DFCI WIDELY PUBLICIZES ITS PATIENT FINANCIAL ASSISTANCE (PFA) POLICY WITHIN ITS FACILITIES, IN DIRECT COMMUNICATIONS WITH PATIENTS AND IN THE COMMUNITIES THAT IT SERVES, PARTICULARLY IN THE COMMUNITIES WITH THE GREATEST UNMET HEALTH NEEDS. THE PFA POLICY, A PLAIN LANGUAGE PFA SUMMARY AND THE PFA APPLICATION ARE POSTED ON DFCI'S WEBSITE IN ENGLISH AND SPANISH. IN ADDITION, INFORMATION ABOUT THE PFA IS PROVIDED TO ALL PATIENTS AT REGISTRATION AND/OR ADMISSION, AND IS AVAILABLE UPON REQUEST, WITHOUT CHARGE, THROUGH A DFCI FINANCIAL COUNSELOR, CUSTOMER SERVICE REPRESENTATIVE, OR BY MAIL. FOLLOWING CARE, ALL BILLING STATEMENTS SENT TO A PATIENT INDICATE HOW THE PATIENT CAN OBTAIN INFORMATION ABOUT THE PFA POLICY. IN COLLABORATION WITH DFCI'S COMMUNITY PARTNERS, INFORMATION ABOUT THE FAP IS SHARED WITH RESIDENTS OF DFCI'S PRIORITY NEIGHBORHOODS. EFFORTS TO NOTIFY COMMUNITY MEMBERS MOST LIKELY TO REQUIRE ASSISTANCE INCLUDE DISTRIBUTING PLAIN LANGUAGE SUMMARIES OF THIS POLICY TO LOCAL COMMUNITY HEALTH CENTERS AND OTHER NON-PROFIT ORGANIZATIONS. Schedule H, Part VI, Line 4 Community information DANA-FARBER SERVES THE COMMUNITY OF EASTERN MASSACHUSETTS AND NEW ENGLAND, INCLUDING THE COMMUNITIES SURROUNDING ITS PRIMARY LOCATION IN BOSTON AND ITS SATELLITE LOCATIONS IN MILFORD, MASSACHUSETTS, WEYMOUTH, MASSACHUSETTS, BRIGHTON, MASSACHUSETTS, NEWTON, MASSACHUSETTS, METHUEN, MASSACHUSETTS AND LONDONDERRY, NEW HAMPSHIRE. DANA-FARBER'S COMMUNITY INCLUDES ADULTS AND CHILDREN WITH CANCER OR AT RISK OF DEVELOPING CANCER, AND THEIR FAMILIES. DANA-FARBER FOCUSES ITS COMMUNITY OUTREACH EFFORTS ON ITS PRIORITY BOSTON NEIGHBORHOODS OF ROXBURY, MISSION HILL, DORCHESTER, MATTAPAN AND JAMAICA PLAIN (WHICH COLLECTIVELY COMPRISE 39% OF BOSTON'S OVERALL POPULATION). TWO OF BOSTON'S MOST POPULATED NEIGHBORHOODS ARE DANA-FARBER PRIORITY NEIGHBORHOODS-DORCHESTER WITH 122,598 RESIDENTS, FOLLOWED BY ROXBURY WITH 49,028. WHITE RESIDENTS NOW MAKE UP LESS THAN HALF OF THE CITY'S RACIAL AND ETHNIC COMPOSITION (46%). BLACK OR AFRICAN AMERICAN RESIDENTS WERE THE SECOND LARGEST RACIAL AND ETHNIC GROUP (23%), FOLLOWED BY HISPANICS (18%) AND ASIANS (9%). THERE IS SUBSTANTIAL VARIATION IN THE RACIAL AND ETHNIC DIVERSITY BY DFCI PRIORITY NEIGHBORHOOD, WITH NEARLY THREE-QUARTERS OF MATTAPAN RESIDENTS AND HALF OF ROXBURY RESIDENTS IDENTIFYING AS BLACK OR AFRICAN AMERICAN. AMONG DANA-FARBER'S PRIORITY NEIGHBORHOODS, ROXBURY AND JAMAICA PLAIN HAVE THE LARGEST HISPANIC POPULATIONS WITH 29% AND 24% RESPECTIVELY, WHILE MISSION HILL AND DORCHESTER HAVE THE LARGEST ASIAN POPULATIONS AMONG THE PRIORITY NEIGHBORHOODS WITH 14% AND 10% RESPECTIVELY. THE MEDIAN INCOMES OF DANA-FARBER'S PRIORITY COMMUNITIES ARE GENERALLY MUCH LOWER THAN BOSTON OVERALL, WITH ROXBURY AT A MEDIAN INCOME OF $25,254, MISSION HILL AT $35,020, AND MATTAPAN AT $42,206. MANY OF DANA-FARBER'S PRIORITY NEIGHBORHOODS, ROXBURY AND MATTAPAN, ARE MORE LIKELY TO HAVE A GREATER POPULATION AT THE LOWER END OF THE INCOME SPECTRUM. RESIDENTS IN DANA-FARBER'S PRIORITY NEIGHBORHOODS APPEAR TO EXPERIENCE HIGHER RATES OF POVERTY THAN BOSTON OVERALL. FEMALE HEADED HOUSEHOLDS ARE ESPECIALLY VULNERABLE, WITH 45% OF ROXBURY FEMALE-HEADED HOUSEHOLDS LIVING BELOW THE POVERTY LINE. DESPITE ITS STATEWIDE REACH AND SERVICES PROVIDED THROUGH OUR SATELLITE OPERATIONS IN WEYMOUTH, ALLSTON/BRIGHTON, AND MILFORD, DANA-FARBER'S PRIORITIZATION OF THESE FIVE NEIGHBORHOODS WITHIN ITS LOCAL SERVICE AREA REFLECTS A COMMITMENT TO REDUCING DISPARITIES IN CANCER CARE AND IMPROVING THE HEALTH AND WELL-BEING OF NEIGHBORHOOD RESIDENTS. THROUGH OUR COLLABORATIVE APPROACH, THE SATELLITE LOCATIONS HAVE AGREED TO LEVERAGE EACH OTHER'S CANCER CONTROL EXPERTISE TO EXPAND AND STRENGTHEN OUR PROGRAMS SUCH AS BRINGING CANCER PREVENTION EFFORTS IN SPANISH TO THE ALLSTON/BRIGHTON AREA. Schedule H, Part VI, Line 5 Promotion of community health DANA-FARBER'S 2022-2025 COMMUNITY HEALTH NEEDS ASSESSMENT AND IMPLEMENTATION PLAN PROVIDE A ROBUST DESCRIPTION OF OUR COMPREHENSIVE CANCER CONTROL PROGRAMS AND SERVICES. THE REPORT ALSO PROVIDES A SUMMARY OF ACCOMPLISHMENTS FROM OUR LAST NEEDS ASSESSMENT AND SETS FORTH OUR COMMITMENT TO ADDRESSING THE NEW OPPORTUNITIES TO REDUCE THE CANCER BURDEN IN MEDICALLY UNDERSERVED COMMUNITIES IN BOSTON. THE REPORTS CAN BE FOUND USING THE FOLLOWING LINKS: COMMUNITY HEALTH NEEDS ASSESSMENT - https://dfci.widen.net/s/rgj28wdsgj/cancer-chna-report-2022.pdf IMPLEMENTATION PLAN - https://dfci.widen.net/s/lkdq7ffjgz/community-health-implementation-plan-2022-25.pdf IN ADDITION, DFCI FURTHERS ITS EXEMPT PURPOSES BY PROMOTING THE HEALTH OF THE COMMUNITY THROUGH DEVOTING THE VAST MAJORITY OF ITS SURPLUS FUNDS TO INSTITUTIONAL SUPPORTED RESEARCH (140 MILLION), BY PROVIDING FINANCIAL ASSISTANCE TO PATIENTS UNABLE TO AFFORD CARE AND BY MAINTAINING A COMMUNITY BOARD. Schedule H, Part VI, Line 7 State filing of community benefit report MA true CITY OF BOSTON City Hall Plaza Boston MA 02114 046001380 115 1611263 Community Support HARVARD UNIVERSITY 60 Oxford St Cambridge MA 02138 042103580 501(c)(3) 1416716 Cancer Research and Devlp Green Roots 90 Everett Ave 3rd FL STE 10 Chelsea MA 02150 812718273 501(c)(3) 200000 Community Support Alternative for Community and Environment with MPHA 2201 Washington St STE 30202 Roxbury MA 02119 043228509 501(c)(3) 200000 Community Support BOSTON ATHLETIC ASSOCIATION 40 TRINITY PLACE 4TH FL BOSTON MA 02116 046111707 501(c)(3) 150000 Community Support WHITTIER STREET HEALTH CENTER 1125 Tremont Street Roxbury MA 02120 042619517 501(c)(3) 67318 Community Support FRIENDS OF DANA-FARBER 450 Brookline Ave Boston MA 02215 371613621 501(c)(3) 50000 Cancer Research and Devlp LEUKEMIA & LYMPHOMA SOCIETY INC 1311 Mamaroneck Ave WHITE PLANES NY 10605 135644916 501(c)(3) 50000 Cancer Research and Devlp PROSTATE HEALTH EDUCATION NETWORK INC 500 Victory Rd 4Th Fl Quincy MA 02453 331042404 501(c)(3) 30000 Cancer Research and Devlp SWIM ACROSS AMERICA INC 8508 Park Road No 389 Charlotte NC 28210 223248256 501(c)(3) 25000 Cancer Research and Devlp MASSACHUSETTS LEAGUE OF COMMUNITY 40 Court St 10Th Floor Boston MA 02108 042507409 501(c)(3) 20000 Community Support COLORECTAL CANCER ALLIANCE INC 1025 Vermont Avenue Nw Suite 1066 Washington DC 20005 860947831 501(c)(3) 20000 Cancer Research and Devlp COMMUNITY SERVINGS INC 179 Arrmory Street Jamaica Plain MA 02130 223154028 501(c)(3) 15000 Community Support BIOMEDICAL SCIENCE CAREERS PROGRAM INC 222 FORBES ROAD SUITE 207 BRAINTREE MA 02184 043241307 501(c)(3) 15000 Community Support ROXBURY COMMUNITY COLLEGE FOUNDATION INC 1234 COLUMBUS AVENUE ROXBURY MA 021203400 222536037 501(c)(3) 15000 Community Support AMERICAN CANCER SOCIETY 250 Williams St Atlanta GA 30303 131788491 501(c)(3) 10000 Cancer Research and Devlp MADISON PARK DEVELOPMENT CORPORATION 184 Dudley St Roxbury MA 02119 237164223 501(c)(3) 10000 Community Support THE BREAST CANCER RESEARCH FOUNDATION 60 EAST 56TH ST 8TH FL NEW YORK NY 10022 133727250 501(c)(3) 10000 Cancer Research and Devlp SUSAN G KOMEN NEW ENGLAND 5005 LBJ FWY STE 370 Dallas TX 75244 751835298 501(c)(3) 10000 Cancer Research and Devlp HEALTH CARE FOR ALL 30 WINTER STREET BOSTON MA 02108 043071598 501(c)(3) 10000 Community Support JOE ANDRUZZI FOUNDATION INC 49 PLAIN ST NORTH ATTLEBORO MA 02760 262017043 501(c)(3) 10000 Cancer Research and Devlp THE CENTER FOR TEEN EMPOWERMENT 130 WARREN ST BOSTON MA 02119 043091002 501(c)(3) 10000 Community Support UNION CAPITAL BOSTON INC 1542 COLUMBUS AVENUE ROXBURY MA 02119 471136081 501(c)(3) 10000 Community Support TEAM MAUREEN Inc PO Box 422 N Falmouth MA 02556 452473500 501(c)(3) 6000 Community Support 23 1 Patient Assistance 887 866891 Miscellaneous Patient Assistance 4429 3146117 FMV Asst Living & Travel Schedule I, Part I, Line 2 Procedures for monitoring use of grant funds. PROCEDURES FOR MONITORING THE USE OF GRANT FUNDS ALL GRANTS AND DONATIONS TO DOMESTIC ORGANIZATIONS WERE GIVEN TO 501(C)(3) ORGANIZATIONS TO FULFILL THEIR MISSIONS, OR GOVERNMENT ENTITIES. ALL GRANT FUNDS TO INDIVIDUALS WERE PROVIDED BASED ON EITHER (AND ONLY) 1) MEANS-TESTED FINANCIAL NEED, OR 2) CLINICALLY DETERMINED IMPROVEMENT TO QUALITY-OF-LIFE. X false X X X X X false true false false false false false true false Laurie H Glimcher MD Trustee, President & CEO 1365076 0 487080 0 148369 0 321693 0 17239 0 2339457 0 0 0 Richard S Boskey ESQ Former Officer 0 0 0 0 108175 0 0 0 0 0 108175 0 0 0 John O Chesley ESQ Counsel 242667 0 0 0 0 0 0 0 35 0 242702 0 0 0 John Ryan ESQ Former Officer 70814 0 93330 0 203 0 5963 0 3866 0 174176 0 0 0 William Hahn MD PHD COO & EVP 837744 0 202254 0 71720 0 42975 0 3538 0 1158231 0 0 0 Michael L Reney CFO and Assistant Treasurer 760613 0 198040 0 61995 0 42975 0 3616 0 1067239 0 0 0 Jennifer Willcox ESQ Asst Secretary & General Counsel 342562 0 75000 0 80568 0 0 0 20595 0 518725 0 0 0 Elizabeth Liebow Former Key Employee 413431 0 74909 0 20510 0 42975 0 25076 0 576901 0 0 0 Sylvia A Bartel RPh MHP VP of Pharmacy Services 316217 0 30075 0 11929 0 42975 0 30846 0 432042 0 0 0 Craig A Bunnell MD Chief Medical Officer 684862 0 128755 0 63453 0 42975 0 6935 0 926980 0 0 0 Melany Duval SVP & Chief Philanthropy Officer 731501 0 127440 0 75358 0 42975 0 19406 0 996680 0 0 0 Benjamin Ebert MD PhD CHAIR OF MEDICAL ONCOLOGY 95763 0 0 0 104276 0 10440 0 2609 0 213088 0 0 0 Wendy Gettleman VP of Facilities Management & Real Estate 340095 0 32243 0 2456 0 42751 0 38004 0 455549 0 0 0 Kevin Haigis Chief Scientific Officer 510289 0 88018 0 45351 0 42975 0 4314 0 690947 0 0 0 Maria Megdal SVP Chief Administrative Officer 507516 0 84272 0 27731 0 42975 0 19409 0 681903 0 0 0 Jeffrey Meyerhardt MD MPH Chief Clinical Research Officer 522423 0 30072 0 33904 0 42975 0 38049 0 667423 0 0 0 Barrett J Rollins MD PHD Sr. Advisor President & CEO 491518 0 0 0 37841 0 42975 0 20753 0 593087 0 0 0 Scott Armstrong MD Chair of Pediatric Oncology 611194 0 109583 0 80673 0 42975 0 30652 0 875077 0 0 0 Michael Constantine MD Milford Med Dir-Hematology/Oncology 675377 0 43015 0 55117 0 27725 0 38019 0 839253 0 0 0 Bruce Johnson MD Sr. Advisor To President & CEO 577360 0 115112 0 52340 0 42704 0 24232 0 811748 0 0 0 Robert Soiffer MD Chair Executive Committee for Clinical Programs 600936 0 148453 0 54147 0 42975 0 20764 0 867275 0 0 0 Mary-Ellen Taplin MD Chair Executive Committee for Clinical Research 513363 0 131785 0 68903 0 42975 0 14864 0 771890 0 0 0 Schedule J, Part I, Line 1a Tax indemnification and gross-up payments FOR THE FOLLOWING, BENEFITS REPORTED IN PART VII INCLUDES GROSS-UP PAYMENTS FOR AN EMPLOYEE RECOGNITION PROGRAM AWARD: 1 KEY EMPLOYEE 1 HIGHEST-COMPENSATED EMPLOYEE Schedule J, Part I, Line 4b Supplemental nonqualified retirement plan THE FOLLOWING INDIVIDUALS PARTICIPATE IN 457(F) PLANS ESTABLISHED BY DFCI; TAXABLE AMOUNTS ARE INCLUDED IN REPORTABLE COMPENSATION IN SCHEDULE J, PART II, COLUMN (B)(III): Laurie Glimcher, MD - $133,537 Richard S. Boskey, ESQ - $108,175 Melany Duval - $72,760 William Hahn, MD, Ph.D - $66,818 Michael Reney - $57,093 Craig A. Bunnell, MD - $47,929 Michael Constantine, MD - $47,593 Kevin Haigis, Ph.D - $42,941 Scott Armstrong, MD - $39,116 Robert Soiffer, MD - $37,582 Bruce Johnson, MD - $34,682 Jeffrey Meyerhardt, MD - $28,484 Mary-Ellen Taplin, MD - $26,778 Maria Megdal - $25,753 Barrett J. Rollins, MD, Ph.D - $23,931 Elizabeth Liebow - $14,675 Sylvia Bartel, RPh, MHP - $2,462 Schedule J, Part I, Line 7 Non-fixed payments DURING THE YEAR, THE CEO, COO, CFO, GENERAL COUNSEL, CERTAIN KEY EMPLOYEES AND HIGHEST COMPENSATED EMPLOYEES WERE ELIGIBLE TO RECEIVE AN INCENTIVE PAYMENT, A PORTION OF WHICH HAS A NON-FIXED PAYMENT PAYABLE AT THE DISCRETION OF THE CEO AND IN THE CASE OF THE CEO, THE BOARD OF TRUSTEES. THE MAXIMUM NON-FIXED PORTION OF THESE INCENTIVE PAYMENTS IS BETWEEN 8% (CEO - 40% MAX, OF THAT 32% TEAM, 8% INDIVIDUAL) AND 4% (SVP - 20% MAX, OF THAT 16% TEAM AND 4% INDIVIDUAL; VP - 10% MAX, OF THAT 6% TEAM AND 4% INDIVIDUAL; AND (EVP - 30% MAX, OF THAT 24% TEAM AND 6% INDIVIDUAL). OTHER REPORTABLE COMPENSATION INCLUDES LOAN FORGIVENESS AND CURRENT YEAR VESTING AMOUNTS IN DANA-FARBER INSTITUTE'S SUPPLEMENTAL NONQUALIFIED RETIREMENT PLAN. A MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2015-08-03 92500000 THE BOND ISSUE WAS USED TO REFUND SERIES L-1 BONDS ISSUED ON 5/22/2008. false false false B MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 05758XNZ0 2016-06-23 282885539 (SEE STATEMENT) false false false C MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 57584YVC0 2019-09-03 60255238 THE BOND ISSUE WAS USED TO REFUND SERIES K BONDS ISSUED ON 5/22/2008. false false false D MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2021-07-28 57500000 THE BOND ISSUE WAS USED TO REFUND SERIES L-2A BONDS ISSUED ON 7/2/2012. false false false A 92500000 92500000 2015 true false true true B 282885539 1099059 2486701 279299779 2019 false false true true C 60255238 1163957 59091281 2019 true false true true D 57500000 57500000 2021 true false true true A false false true true true true 0.0 false false true B false false false true true 0.0 false false true C false false true true true true 0.0 false false true D false false true true true true 0.0 false false true A false false false true true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false false true B false false false true false false false false true C false false false true false false false false true D false false true false true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false false true A true B true C true D true Schedule K, Part I, Column (f) B (F) DESCRIPTION OF PURPOSE THE BOND ISSUE WAS USED TO PARTIALLY COVER THE ACQUISITION AND FIT-OUT OF RESEARCH SPACE AND VIVARIUM AT THE LONGWOOD CENTER; TO PARTIALLY COVER THE REPLACEMENT OF HVAC SYSTEM AT THE SMITH BUILDING; TO COVER THE RELOCATION TO, RECONSTRUCTION AND EQUIPPING OF THE INSTITUTE'S CELL MANIPULATION CORE FACILITY; AND TO COVER THE COSTS OF BOND ISSUANCE AND INTEREST DURING THE CONSTRUCTION PERIOD AS WELL AS OTHER CAPITAL PROJECTS. Schedule K, Part IV SCHEDULE K, PART IV (ARBITRAGE) D 2(b) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception. E 2(b) This issuance was refunded in 2021 and had no invested assets and qualifies for 6-month spending exception. Schedule K, Part II (PROCEEDS) B 3 THE TOTAL PROCEEDS OF $282,885,539 INCLUDE INVESTMENT EARNINGS IN THE AMOUNT OF $1,099,059. Schedule K, Part IV, Line 2c COLUMN A Issuer name: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY The calculation for computing no rebate due was performed on 11/01/2020 Schedule K, Part IV, Line 2c COLUMN B Issuer name: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY The calculation for computing no rebate due was performed on 11/01/2020 Schedule K, Part IV, Line 2c COLUMN C Issuer name: MASSACHUSETTS DEVELOPMENT FINANCE AGENCY The calculation for computing no rebate due was performed on 11/01/2020 A MASSACHUSETTS DEVELOPMENT FINANCE AGENCY 043431814 2021-07-28 35000000 THE BOND ISSUE WAS USED TO REFUND SERIES L-2B BONDS ISSUED ON 7/2/2012. false false false A 35000000 35000000 2021 true false true true A false false true true true true 0.0 false false true A false false true false true true MORGAN STANLEY CAPITAL SERVICES INC 39.8 false false false false true A true Melany Duval Employee Housing Loan X 150000 78750 false true true Kevin Haigis Employee Housing Loan X 100000 65833 false true true Benjamin Ebert Employee Housing Loan X 500000 33334 false true true 177917 X 1654125 Other X 231 17503981 Other - Fair Market Value X 9 53781 Other - MARKET VALUE PER DONOR X Event Tickets 2 418700 Other - MARKET VALUE PER DONOR X MISCELLANEOUS 5 213507 Other - MARKET VALUE PER DONOR X EQUIPMENT 3 196750 Other - MARKET VALUE PER DONOR false true true Schedule M, Part I COLUMN (B) DANA-FARBER CANCER INSTITUTE, INC. IS REPORTING THE NUMBER OF CONTRIBUTIONS RECEIVED. Schedule M, Part I, Line 32b Third parties used to solicit, process, or sell noncash contributions DANA-FARBER CANCER INSTITUTE, INC. HAS AN ARRANGEMENT WITH ANOTHER CHARITY PURSUANT TO WHICH THE OTHER CHARITY ACCEPTS CERTAIN NONCASH DONATIONS FOR THE BENEFIT OF DANA-FARBER. PROCEEDS FROM THE SALE OF NONCASH DONATIONS ARE DIRECTED TO A DESIGNATED FUND FOR THE BENEFIT OF DANA-FARBER. IN ADDITION, DANA-FARBER HAS AN ARRANGEMENT WITH ANOTHER CHARITY PURSUANT TO WHICH THE OTHER CHARITY ACCEPTS VEHICLE DONATIONS FOR THE BENEFIT OF DANA-FARBER. PROCEEDS FROM THE SALE OF DONATED VEHICLES ARE DIRECTED TO DANA-FARBER. Schedule M, Part I, Line 33 Noncash contribution amounts not reported DANA-FARBER CANCER INSTITUTE, INC. RECEIVED DONATIONS OF ART, BOOKS, AND OTHER GOODS THAT IT DISPLAYS IN ITS PROPERTIES. THESE GOODS HAVE VALUES THAT ARE EITHER NOMINAL OR ARE NOT READILY DETERMINABLE AND ARE, THEREFORE, NOT INCLUDED AS REVENUE. Form 990, Part I, Line 1 Organization's mission THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. Form 990, Part III, Line 1 Organization's mission THE MISSION OF DFCI IS TO PROVIDE EXPERT, COMPASSIONATE, AND EQUITABLE CARE TO CHILDREN, ADULTS, AND THEIR FAMILIES, WHILE ADVANCING THE UNDERSTANDING, DIAGNOSIS, TREATMENT, CURE, AND PREVENTION OF CANCER AND RELATED DISEASES. WE TRAIN NEW GENERATIONS OF CLINICIANS AND SCIENTISTS, DISSEMINATE INNOVATIVE PATIENT THERAPIES AND SCIENTIFIC DISCOVERIES AROUND THE WORLD, AND REDUCE THE IMPACT OF CANCER, WHILE AT ALL TIMES MAINTAINING A FOCUS ON THOSE COMMUNITIES THAT HAVE BEEN HISTORICALLY MARGINALIZED. Form 990, Part III, Line 4a Program Service Accomplishments CLINICAL CARE As one of the leading cancer centers in the world, Dana-Farber Cancer Institute provides compassionate, comprehensive, and personalized care to adults and children with cancer, blood disorders, and related diseases. In fiscal year 2023, our expert clinicians and caregivers at our specialized treatment centers worked together to deliver the latest therapies to our patients through 1,300 inpatient admissions, 384,094 outpatient MD visits, and 217,279 infusion treatments. Since its founding in 1947 by Sidney Farber, MD, Dana-Farber has followed his vision for a cancer center that is just as dedicated to discoveries in cancer research as it is to delivering expert, compassionate care. Our Institute is a founding member of Dana-Farber/Harvard Cancer Center and one of 56 NCI-designated Comprehensive Cancer Centers in the U.S. We are the only hospital ranked in the top four nationally by U.S News and World Report in both adult and pediatric cancer care. In 2023, we offered more than 1,100 clinical trials. Form 990, Part III, Line 4b Program Service Accomplishments RESEARCH Scientific work at Dana-Farber is based on the premise that basic and clinical investigation are complementary and reinforcing activities. To encourage this cross-pollination of ideas, the Institute has developed an organizational framework that fosters collaborations among investigators from different disciplines. The result is an intense scientific impact on a group of diseases that continue to represent one of humanity's greatest health challenges. Some recent advances include: Immunotherapy After Surgery Improves Survival in Kidney Cancer: A clinical trial led by Dana-Farber investigators showed that treatment with the immunotherapy drug pembrolizumab after surgery can significantly prolong the survival of patients with clear-cell renal-cell carcinoma at high risk for recurrence. Blood Test Can Detect Subtype of Advanced Prostate Cancer: A blood test developed by researchers at Dana-Farber and the University of Trento, Italy, can reliably detect neuroendocrine prostate cancer and distinguish it from metastatic castration-resistant prostate cancer. Dual-Acting Agent Effective in Multiple Myeloma: Mezigdomide, a new agent that acts as both a targeted drug and an immunotherapy produced impressive results when combined with an anti-inflammatory drug in patients with relapsed multiple myeloma that didn't respond to other therapies, an international clinical trial co-led by Dana-Farber investigators found. Test for Circulating DNA May Predict Relapse in Patients with Diffuse Large B-cell Lymphoma: A pilot study by researchers from Dana-Farber and the Broad Institute demonstrated that a novel test for circulating tumor DNA was more sensitive than existing techniques for detecting relapse in patients with diffuse large B-cell lymphoma after an autologous stem cell transplant. Antibody Drug Sharply Reduces Risk of Severe Chronic Graft-Versus-Host Disease in Patients Undergoing Allogeneic Stem Cell Transplant: In patients who have undergone a donor stem cell transplant, preventive treatment with the drug obinutuzumab can sharply reduce the risk of developing chronic graft-versus-host disease severe enough to require treatment with systemic steroids, a clinical trial led by Dana-Farber investigators found. Bispecific Antibody Drug Drives Myeloma Precursor Condition to Undetectable Levels: In the first clinical trial of an immunotherapy agent for people with high-risk smoldering myeloma - a precursor of multiple myeloma - a bispecific antibody therapy eliminated all signs of the condition in every patient evaluated to date, Dana-Farber researchers reported. Online Tool Enables Users to Quickly Assess Their Risk of Breast and Ovarian Cancer: An online tool developed by Dana-Farber specialists in women's cancers includes a simple quiz to help individuals gauge their risk of developing breast or ovarian cancer. Shorter Course of Radiation Therapy Is Safe for Patients with Early-Stage Breast Cancer Who Have Undergone Mastectomy: Dana-Farber researchers found that a shorter course of radiation therapy after mastectomy and breast reconstruction surgery provides the same protection against breast cancer recurrence but substantially reduces life disruption and financial burden for patients. Artificial Intelligence Tool Can Predict Primary Source of Cancer: Dana-Farber researchers created an AI-based tool that uses tumor gene sequencing data to predict the primary source of a patient's cancer. The tool could help guide cancer treatment and improve outcomes in difficult-to-diagnose cases. Targeted Drug Lengthens Survival in Patients with a Form of Glioma: In a clinical trial co-led by Dana-Farber investigators, the targeted drug vorasidenib more than doubled progression-free survival in patients with Grade 2 glioma brain tumors carrying mutations in the genes IDH1 and IDH2. Study Shows Many Younger Women with Breast Cancer Can Safely Have a Baby: A study by Dana-Farber researchers found that for young women with hormone receptor-positive breast cancer, pausing endocrine therapy to pursue a pregnancy did not raise the short-term risk that the disease will recur. New Tool Helps Pinpoint Patients at High Risk for Blood Cancer: A clinical tool developed by a team of Dana-Farber researchers can identify patients with clonal hematopoiesis - a symptomless condition that increases the risk of certain blood cancers - are at highest risk of developing those cancers. Diagnostic Services in a Community Health Center Can Speed Cancer Diagnosis for Underserved Populations: Offering cancer diagnostic services in a community health center caring for underserved populations can reduce the time it takes to diagnose the disease in these groups, Dana-Farber researchers reported. Form 990, Part III, Line 4c Program service accomplishments COMMUNITY BENEFITS The role of Dana-Farber's Community Benefits office is to support the Institute's goal to reduce cancer risk among medically underserved populations. We work with city and state health departments, community partners, and Boston-based coalitions to assess and monitor the needs of local residents with respect to cancer control. In collaboration with staff throughout Dana-Farber, we serve as a bridge with community organizations and establish evidence-based and sustainable outreach programs. We are on the front lines of supporting and collaborating on programs designed to eliminate disparities in breast, colon, and skin cancer; educate diverse populations about tobacco cessation, human papillomavirus (HPV) prevention and screening; and strengthen the support system for medically underserved populations. In short, we are committed to making Dana-Farber's care and research findings more accessible to everyone within and outside its walls. In Fiscal Year 2023: A total of 2,105 individuals were reached through 25 community education, outreach, and screening events. FY23 programmatic highlights are as follows: The Community-Facing Patient Navigation Program has been successfully integrated to serve patients with Gastrointestinal, Breast, Thoracic and Gynecologic cancers, as well as Lymphoma and Multiple Myeloma. Dana-Farber's mammography services provided 2,228 mammograms on the van and at the mammography suite at Whittier Street Health Center in Roxbury. Dana-Farber's Sun Safety Program provided 16 in-person sun safety screening events with added health and safety measures. 841 participants were screened by a dermatologist and 130 people were referred for follow-up appointments. 50 participants were referred for a biopsy. Dana-Farber's Tobacco Treatment program received 88 referrals and provided 72 individual tobacco cessation counseling sessions to 28 patients. 20 participants were able to reduce their total number of cigarettes smoked per day, and 12 of these reported being able to quit completely. The Tobacco Treatment program continued to provide financial incentives for participants enrolled in the program. Stop and Shop gift cards were provided after each counseling session to encourage individuals to reduce their tobacco usage and quit smoking. Developed and optimized AssessYourRisk, a digital tool to help women of all ages assess and manage their breast and ovarian cancer risk. Dana-Farber implemented and evaluated the second year of Dana-Farber's multi-year Systems Level Funding, awarded to four non-profit organizations in Greater Boston to address environmental justice, food insecurity, and child homelessness. Successes from the second year include raising awareness, building resident power, and gathering evidence for advocacy in pursuit of creating meaningful policy, systems and environmental (PSE) change. Additionally, lessons learned about evaluating a multi-year PSE initiative were disseminated through a poster at a national meeting. The Community Health Office partnered with Union Capital Boston and DF/HCC to host four virtual Cancer Awareness Resource Nights focused on multiple myeloma, cancer clinical trials, cancer survivorship, and uterine and endometrial cancers, engaging approximately 120 residents per event. These events featured an education session on a cancer-related topic, survivor testimony, and Q&A sessions with audience members. The Community Health Office expanded health education and outreach opportunities with two new bilingual Community Outreach Specialists focused on women's health and the Asian community. Dana-Farber expanded and strengthened the process of collecting accurate and complete patient demographic data, including launching routine collection of sexual orientation and gender identity information. Dana-Farber analyzed data from mammography van patients and implemented strategies to increase awareness around timely imaging following abnormal breast cancer screening results. Dana-Farber conducted a systematic analysis of patient experience by demographic groups and identified several gaps and actionable areas for improvement. Form 990, Part VI, Line 2 Family/business relationships amongst interested persons ANDREW JANOWER AND MICHAEL EISENSON - Business relationship, JOSH BEKENSTEIN, ANDREW KAPLAN, AND NANCY LOTANE - Business relationship, PHILLIP GROSS AND DEMOND MARTIN - Business relationship, RICHARD LUBIN, CHRISTOPHER HADLEY, AND JANE BROCK-WILSON - Business relationship, SUSHIL TULI AND PETER PALANDJIAN - Business relationship, BRIAN KNEZ AND JESSICA KNEZ - Family relationship, JOHN O'CONNOR AND LAURA SEN - Family relationship Form 990, Part VI, Line 11b Review of form 990 by governing body THE DANA-FARBER CANCER INSTITUTE TAX DEPARTMENT PROVIDES ALL FINANCIAL ANALYSIS AND OTHER INFORMATION TO BE INCLUDED ON THE TAX RETURN TO ITS EXTERNAL TAX PREPARER, ERNST & YOUNG LLP, WHICH PREPARES THE DRAFT RETURN. THE DRAFT RETURN IS THEN REVIEWED BY THE DFCI TAX MANAGER, AS WELL AS THE DFCI OFFICE OF GENERAL COUNSEL AND SENIOR MANAGEMENT, BEFORE IT IS SUBMITTED FOR DFCI AUDIT COMMITTEE REVIEW. AFTER THE AUDIT COMMITTEE REVIEWS THE TAX RETURN, AN ELECTRONIC MESSAGE IS SENT TO ALL GOVERNING BOARD MEMBERS WITH A SECURE LINK TO THE TAX RETURN. THE BOARD HAS THE OPPORTUNITY TO REVIEW THE RETURN AND BRING ANY ISSUES TO THE ATTENTION OF THE APPROPRIATE EXECUTIVE MANAGEMENT INDIVIDUALS. A FINAL VERSION OF THE FORM IS APPROVED BY THE CFO AND FILED ELECTRONICALLY BY ERNST & YOUNG LLP WITH THE IRS. Form 990, Part VI, Line 12c Conflict of interest policy DFCI MONITORS AND ENFORCES COMPLIANCE WITH THE DFCI CONFLICT-OF-INTEREST AND CONFIDENTIALITY POLICY FOR BOARD OFFICERS, TRUSTEES, AND KEY EMPLOYEES ("COVERED PERSONS"). THE OFFICE OF THE GENERAL COUNSEL ANNUALLY DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE AND CONFIDENTIALITY STATEMENT ("STATEMENT") REQUIRING ALL COVERED PERSONS TO DISCLOSE INTERESTS, ROLES, AND ACTIVITIES THAT COULD GIVE RISE TO A POTENTIAL OR ACTUAL CONFLICT WITH THE INTERESTS OF DFCI. IF A TRUSTEE FAILS TO COMPLETE THE ANNUAL STATEMENT, THE CHAIR OF THE GOVERNANCE COMMITTEE MAY TAKE ACTIONS TO SUSPEND THE TRUSTEE. DFCI REQUIRES COVERED PERSONS TO COMPLETE THE STATEMENT UPON INITIAL APPOINTMENT TO A COVERED OFFICE AND TO UPDATE THEIR DISCLOSURES ON A CONTINUING BASIS WHENEVER A COVERED PERSON BECOMES AWARE OF A NEW OR PREVIOUSLY UNDISCLOSED INTEREST. THE OFFICE OF GENERAL COUNSEL COMPARES THE DISCLOSURES TO INSTITUTIONAL INFORMATION IN ORDER TO IDENTIFY POTENTIAL OR ACTUAL CONFLICTS OF INTEREST. THE DFCI GENERAL COUNSEL REPORTS ON ALL DISCLOSURES TO THE DFCI PRESIDENT, CHAIR OF THE DFCI BOARD AND CHAIR OF THE DFCI BOARD GOVERNANCE COMMITTEE. THE BOARD IS RESPONSIBLE UNDER THE COI POLICY FOR ADDRESSING ISSUES RELATED TO CONFLICTS OF COVERED PERSONS. A PROPOSED ARRANGEMENT CREATING A CONFLICT OF INTEREST MAY BE APPROVED IF APPROPRIATE STEPS ARE TAKEN TO ENSURE THAT DFCI MAKES A DECISION IN AN OBJECTIVE AND FAIR MANNER CONSISTENT WITH THE HIGHEST ETHICAL AND LEGAL STANDARDS. SUCH STEPS INCLUDE RECUSAL OF THE COVERED PERSON WITH A CONFLICT OF INTEREST FROM NEGOTIATIONS OR DISCUSSIONS ON BEHALF OF DFCI OR THE ENTITY WITH WHICH DFCI IS DOING BUSINESS AND FROM BOARD OR DFCI MANAGEMENT DISCUSSIONS OF SUCH ARRANGEMENT. Form 990, Part VI, Line 15a Process to establish compensation of top management official PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES REVIEWS THE PRESIDENT'S (DFCI'S CHIEF EXECUTIVE OFFICER) PERFORMANCE AND MAKES A RECOMMENDATION REGARDING COMPENSATION TO THE EXECUTIVE COMMITTEE. THE EXECUTIVE COMMITTEE ACTS ON THE RECOMMENDATION. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE COMPENSATION COMMITTEE ANNUALLY COMMISSIONS AN INDEPENDENT REVIEW BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT TO COMPARE SUCH COMPENSATION WITH THAT OF OTHER SIMILARLY SITUATED INDIVIDUALS IN THE HEALTHCARE FIELD IN AND OUTSIDE OF THE REGION. THE DECISION OF THE EXECUTIVE COMMITTEE IS REPORTED TO THE FULL BOARD. THE BOARD COMPLETED THIS PROCESS AS OF JANUARY 2023. Form 990, Part VI, Line 15b Process to establish compensation of other employees PROCESS FOR DETERMINING COMPENSATION OF OFFICERS AND KEY EMPLOYEES PER DFCI'S EXECUTIVE COMPENSATION PHILOSOPHY, ANNUALLY THE DFCI PRESIDENT REVIEWS THE PERFORMANCE OF OFFICERS AND KEY EMPLOYEES. THE PRESIDENT MAKES A RECOMMENDATION AS TO THE COMPENSATION OF THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES COMPENSATION FOR THOSE INDIVIDUALS BASED ON THAT RECOMMENDATION. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF COMPENSATION FOR THOSE INDIVIDUALS. TO ENSURE COMPLIANCE WITH THE PHILOSOPHY, THE PRESIDENT AND COMPENSATION COMMITTEE ANNUALLY RECEIVE A REPORT BY A THIRD-PARTY EXECUTIVE COMPENSATION CONSULTANT. THE REPORT ANALYZES THE COMPETITIVENESS OF THE TOTAL COMPENSATION PROGRAM FOR DISQUALIFIED PERSONS AGAINST MARKET DATA REPRESENTING DFCI'S LOCAL AND NATIONAL PEER ORGANIZATIONS. THE PRESIDENT MAKES RECOMMENDATIONS FOR MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS WHO ARE DISQUALIFIED PERSONS OF DFCI TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES. THE COMPENSATION COMMITTEE APPROVES MARKET ADJUSTMENTS FOR THOSE INDIVIDUALS BASED ON THE PRESIDENT'S RECOMMENDATION. THE BOARD COMPLETED THIS PROCESS AS OF JUNE 2022. FOR KEY EMPLOYEES WHO ARE NOT DISQUALIFIED PERSONS, THE PRESIDENT REPORTS TO THE COMPENSATION COMMITTEE OF THE BOARD OF TRUSTEES ON HER DETERMINATION OF MARKET ADJUSTMENTS AS NEEDED FOR THOSE INDIVIDUALS. Form 990, Part VI, Line 19 Required documents available to the public GOVERNING DOCUMENTS: THE GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST. THESE DOCUMENTS ARE ALSO AVAILABLE TO THE PUBLIC ON THE SECRETARY OF THE COMMONWEALTH'S WEBSITE. CONFLICT OF INTEREST POLICY: DANA-FARBER CANCER INSTITUTE'S BOARD OF TRUSTEES CONFLICT OF INTEREST POLICY IS AVAILABLE UPON REQUEST. FINANCIAL STATEMENTS: THE ORGANIZATION USES THE SERVICES OF DIGITAL ASSURANCE CERTIFICATION LLC (DAC) TO REPORT ANNUAL AUDITED FINANCIAL STATEMENTS AND OTHER RELEVANT ORGANIZATIONAL INFORMATION AS REQUIRED BY CERTAIN REGULATORY AND TAX LAWS. DAC IS A WEBSITE (WWW.DACBOND.COM) FREE TO THE PUBLIC THAT PUBLISHES TAX-EXEMPT BOND ISSUERS' FINANCIAL AND LEGAL DOCUMENTS SUCH AS THE AUDITED FINANCIAL STATEMENTS. FISCAL YEAR 2016 THROUGH THE LATEST ISSUE DATE OF THE AUDITED FINANCIAL STATEMENTS FOR DANA-FARBER CANCER INSTITUTE, INC. CAN BE FOUND ON THE DAC WEBSITE. ANNUAL AUDITED FINANCIAL STATEMENTS FROM FISCAL YEAR 1998 THROUGH FISCAL YEAR 2015 ARE AVAILABLE UPON REQUEST. Form 990, Part VIII, Line 11d Other Miscellaneous Revenue OTHER REVENUE - Total Revenue: 3125300, Related or Exempt Function Revenue: , Unrelated Business Revenue: , Revenue Excluded from Tax Under Sections 512, 513, or 514: 3125300; Form 990, Part XI, Line 9 Other changes in net assets or fund balances CHANGE IN INTEREST IN ASSETS HELD BY AFFILIATES - XXX-XX-XXXX; CHANGE IN VALUE OF SWAP AGREEMENT - 8826726; PENSION ADJUSTMENT - 764299; DANA-FARBER GLOBAL ONCOLOGY LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 851914853 INTERNATIONAL ONCOLOGY MA -1239623 7361691 DFCI BINNEY STREET CAPITAL FUND LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 INVESTMENTS DE -1177601 5340764 DFI Dana-Farber National Workforce LLC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 921748999 Professional employer organization MA 0 0 DFCI DANA-FARBER INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043102433 INVESTMENT MANAGEMENT MA 501(c)(3) Type I DFCI true THE DANA-FARBER TRUST INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 300195757 RECEIVE REAL ESTATE GIFTS FOR DFCI MA 501(c)(3) Type I DFCI true DANA-FARBERMASS GEN BRIGHAM CANCER CARE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043320640 ONCOLOGY RESEARCH MA 501(c)(3) Type I NA false RMSA TRUST 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 562656539 VEBA TRUST MA 501(c)(9) DFCI true FRIENDS OF DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 371613621 FUNDRAISING MA 501(c)(3) Type I DFCI true DANA-FARBERCHILDREN'S HOSP CANCER CARE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 043554536 PEDIATRIC ONCOLOGY MA 501(c)(3) Type I NA false DANA-FARBER CANCER CARE NETWORK INC 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 465138314 ONCOLOGY CARE MA 501(c)(3) 10 DFCI true MGB DF INTL LLC 399 REVOLUTION DR STE 645 SOMERVILLE MA 02145 871595882 INTERNATIONAL CONSULTING DE NA N/A -136539 -141806 false false 0.5 false true true false false false false false false false false true false false true false false true true Dana-Farber Cancer Care Network Inc R 43952242 CASH Dana-Farber Cancer Care Network Inc S 173047 Cash DANA-FARBER INC S 291690864 Cash DANA-FARBER INC R 235240047 Cash FRIENDS OF DANA-FARBER CANCER INSTITUTE INC C 816813 CASH FRIENDS OF DANA-FARBER CANCER INSTITUTE INC O 311503 ACTUAL EXP RMSA Trust R 370629 Cash